URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Submission: On April 08 via manual from JP — Scanned from JP

Summary

This website contacted 27 IPs in 4 countries across 19 domains to perform 112 HTTP transactions. The main IP is 34.149.36.179, located in Kansas City, United States and belongs to GOOGLE, US. The main domain is www.oncozine.com.
TLS certificate: Issued by R3 on March 25th 2024. Valid for: 3 months.
This is the only time www.oncozine.com was scanned on urlscan.io!

urlscan.io Verdict: No classification

Domain & IP information

IP Address AS Autonomous System
27 34.149.36.179 15169 (GOOGLE)
3 2404:6800:400... 15169 (GOOGLE)
1 2404:6800:400... 15169 (GOOGLE)
1 54.231.132.161 16509 (AMAZON-02)
5 216.58.220.130 15169 (GOOGLE)
1 2404:6800:400... 15169 (GOOGLE)
1 2606:4700:303... 13335 (CLOUDFLAR...)
12 172.67.159.150 13335 (CLOUDFLAR...)
12 172.66.42.247 13335 (CLOUDFLAR...)
2 2606:4700::68... 13335 (CLOUDFLAR...)
3 2404:6800:400... 15169 (GOOGLE)
1 6 2a02:6b8::1:119 13238 (YANDEX)
1 2a03:2880:f10... 32934 (FACEBOOK)
1 2600:9000:215... 16509 (AMAZON-02)
4 2404:6800:400... 15169 (GOOGLE)
2 52.92.148.72 16509 (AMAZON-02)
4 172.217.175.72 15169 (GOOGLE)
1 2606:4700::68... 13335 (CLOUDFLAR...)
9 142.250.196.142 15169 (GOOGLE)
1 172.66.41.9 13335 (CLOUDFLAR...)
1 142.251.42.194 15169 (GOOGLE)
1 2404:6800:400... 15169 (GOOGLE)
1 2 52.38.207.187 16509 (AMAZON-02)
2 172.67.204.94 13335 (CLOUDFLAR...)
1 2404:6800:400... 15169 (GOOGLE)
1 2a00:1450:401... ()
112 27
Apex Domain
Subdomains
Transfer
27 oncozine.com
www.oncozine.com
1 MB
13 infolinks.com
resources.infolinks.com — Cisco Umbrella Rank: 5921
router.infolinks.com — Cisco Umbrella Rank: 2497
rt3073.infolinks.com — Cisco Umbrella Rank: 60022
305 KB
12 google-analytics.com
www.google-analytics.com — Cisco Umbrella Rank: 35
21 KB
12 trendmd.com
js.trendmd.com — Cisco Umbrella Rank: 30958
www.trendmd.com — Cisco Umbrella Rank: 27875
css.trendmd.com — Cisco Umbrella Rank: 29571
academia.trendmd.com — Cisco Umbrella Rank: 29209
51 KB
7 googletagmanager.com
www.googletagmanager.com — Cisco Umbrella Rank: 43
578 KB
6 yandex.ru
mc.yandex.ru — Cisco Umbrella Rank: 4290
81 KB
5 gstatic.com
fonts.gstatic.com
csi.gstatic.com
95 KB
5 googlesyndication.com
pagead2.googlesyndication.com — Cisco Umbrella Rank: 115
209 KB
3 izooto.com
cdn.izooto.com — Cisco Umbrella Rank: 13831
79 KB
3 amazonaws.com
trendmd.s3.amazonaws.com — Cisco Umbrella Rank: 175675
s3-us-west-2.amazonaws.com
163 KB
2 trendmd.co
cc.trendmd.co — Cisco Umbrella Rank: 28254
3 KB
2 trustedsite.com
www.trustedsite.com — Cisco Umbrella Rank: 21786
2 KB
2 doubleclick.net
googleads.g.doubleclick.net — Cisco Umbrella Rank: 39
securepubads.g.doubleclick.net — Cisco Umbrella Rank: 212
556 B
2 googleapis.com
fonts.googleapis.com — Cisco Umbrella Rank: 38
imasdk.googleapis.com — Cisco Umbrella Rank: 508
137 KB
1 ywxi.net
cdn.ywxi.net — Cisco Umbrella Rank: 12616
6 KB
1 facebook.com
www.facebook.com — Cisco Umbrella Rank: 99
1 gdcstatic.com
secure.gdcstatic.com — Cisco Umbrella Rank: 969349
104 KB
1 ampproject.org
cdn.ampproject.org — Cisco Umbrella Rank: 392
24 KB
0 tnewstraffic.com Failed
cloud.tnewstraffic.com Failed
112 19
Domain Requested by
27 www.oncozine.com www.oncozine.com
12 www.google-analytics.com www.googletagmanager.com
www.google-analytics.com
www.oncozine.com
8 resources.infolinks.com www.oncozine.com
resources.infolinks.com
7 www.googletagmanager.com www.oncozine.com
www.googletagmanager.com
www.google-analytics.com
js.trendmd.com
6 www.trendmd.com js.trendmd.com
6 mc.yandex.ru 1 redirects secure.gdcstatic.com
www.oncozine.com
mc.yandex.ru
5 pagead2.googlesyndication.com www.oncozine.com
pagead2.googlesyndication.com
4 fonts.gstatic.com fonts.googleapis.com
3 css.trendmd.com js.trendmd.com
css.trendmd.com
3 router.infolinks.com resources.infolinks.com
3 cdn.izooto.com www.oncozine.com
cdn.izooto.com
2 academia.trendmd.com js.trendmd.com
2 cc.trendmd.co js.trendmd.com
2 www.trustedsite.com 1 redirects www.oncozine.com
2 rt3073.infolinks.com resources.infolinks.com
2 s3-us-west-2.amazonaws.com cdn.ywxi.net
1 csi.gstatic.com pagead2.googlesyndication.com
1 securepubads.g.doubleclick.net imasdk.googleapis.com
1 imasdk.googleapis.com resources.infolinks.com
1 googleads.g.doubleclick.net pagead2.googlesyndication.com
1 cdn.ywxi.net www.oncozine.com
1 www.facebook.com www.oncozine.com
1 js.trendmd.com www.oncozine.com
1 secure.gdcstatic.com www.oncozine.com
1 cdn.ampproject.org www.oncozine.com
1 trendmd.s3.amazonaws.com www.oncozine.com
1 fonts.googleapis.com www.oncozine.com
0 cloud.tnewstraffic.com Failed secure.gdcstatic.com
112 28
Subject Issuer Validity Valid
*.oncozine.com
R3
2024-03-25 -
2024-06-23
3 months crt.sh
*.google-analytics.com
GTS CA 1C3
2024-03-04 -
2024-05-27
3 months crt.sh
upload.video.google.com
GTS CA 1C3
2024-03-04 -
2024-05-27
3 months crt.sh
*.s3.amazonaws.com
Amazon RSA 2048 M01
2023-10-10 -
2024-07-03
9 months crt.sh
*.g.doubleclick.net
GTS CA 1C3
2024-03-04 -
2024-05-27
3 months crt.sh
misc-sni.google.com
GTS CA 1C3
2024-03-04 -
2024-05-27
3 months crt.sh
gdcstatic.com
GTS CA 1P5
2024-02-26 -
2024-05-26
3 months crt.sh
trendmd.com
GTS CA 1P5
2024-03-30 -
2024-06-28
3 months crt.sh
sni.cloudflaressl.com
Cloudflare Inc ECC CA-3
2023-05-15 -
2024-05-14
a year crt.sh
mc.yandex.ru
GlobalSign ECC OV SSL CA 2018
2023-12-26 -
2024-06-05
5 months crt.sh
*.facebook.com
DigiCert SHA2 High Assurance Server CA
2024-01-16 -
2024-04-15
3 months crt.sh
*.ywxi.net
Amazon RSA 2048 M02
2023-06-05 -
2024-07-03
a year crt.sh
*.gstatic.com
GTS CA 1C3
2024-03-04 -
2024-05-27
3 months crt.sh
*.s3-us-west-2.amazonaws.com
Amazon RSA 2048 M01
2024-03-15 -
2025-02-15
a year crt.sh
trendmd.co
E1
2024-03-29 -
2024-06-27
3 months crt.sh

This page contains 5 frames:

Frame: https://cloud.tnewstraffic.com/?news&s
Frame ID: 68BBB7A22112D9D7553FCA340589C6D5
Requests: 106 HTTP requests in this frame

Frame: https://www.facebook.com/plugins/like.php?href=https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/&layout=button_count&show_faces=false&width=105&action=like&colorscheme=light&height=21
Frame ID: D45C6986D7A8DB7B49B5E2C0B6388750
Requests: 1 HTTP requests in this frame

Frame: https://router.infolinks.com/usync/manage?pid=3379170&wsid=0&pdom=www.oncozine.com&purl=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F
Frame ID: 275828128EF7043FD9478A9FFFAF8C94
Requests: 1 HTTP requests in this frame

Frame: https://cdn.izooto.com/scripts/sak/iz_setcid.html?v=1
Frame ID: 3DFDFBC5C7FB93251F4E44B887F3BFAE
Requests: 1 HTTP requests in this frame

Frame: https://googleads.g.doubleclick.net/pagead/ads?client=ca-pub-8204247984439341&output=html&adk=1812271804&adf=3025194257&lmt=1712570847&plat=1%3A16777216%2C2%3A16777216%2C3%3A16%2C4%3A16%2C9%3A32776%2C16%3A8388608%2C17%3A32%2C24%3A32%2C25%3A32%2C30%3A1081344%2C32%3A32%2C41%3A32%2C42%3A32&format=0x0&url=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&pra=5&wgl=1&easpi=0&asro=0&uach=WyJXaW4zMiIsIjEwLjAuMCIsIng4NiIsIiIsIjEyMy4wLjYzMTIuMTA1IixudWxsLDAsbnVsbCwiNjQiLFtbIkdvb2dsZSBDaHJvbWUiLCIxMjMuMC42MzEyLjEwNSJdLFsiTm90OkEtQnJhbmQiLCI4LjAuMC4wIl0sWyJDaHJvbWl1bSIsIjEyMy4wLjYzMTIuMTA1Il1dLDBd&dt=1712570847721&bpp=2&bdt=1457&idt=209&shv=r20240403&mjsv=m202404020101&ptt=9&saldr=aa&abxe=1&nras=1&correlator=5137455438121&rume=1&frm=20&pv=2&ga_vid=227320689.1712570847&ga_sid=1712570848&ga_hid=601469149&ga_fc=1&u_tz=540&u_his=2&u_h=600&u_w=800&u_ah=600&u_aw=800&u_cd=24&u_sd=1&dmc=8&adx=-12245933&ady=-12245933&biw=1600&bih=1113&scr_x=0&scr_y=0&eid=44759875%2C44759926%2C44759837%2C95329025%2C95329439%2C95329462%2C95329571%2C31081717%2C31061691%2C31061692&oid=2&pvsid=4282168737799688&tmod=702938097&uas=0&nvt=1&fsapi=1&fc=1920&brdim=170%2C170%2C170%2C170%2C800%2C0%2C1600%2C1200%2C1600%2C1113&vis=1&rsz=%7C%7Cs%7C&abl=NS&fu=32768&bc=31&bz=1&psd=W251bGwsbnVsbCxudWxsLDNd&ifi=1&uci=a!1&fsb=1&dtd=230
Frame ID: 4119B077161A62A18168566FAB673AF8
Requests: 1 HTTP requests in this frame

Screenshot

Page Title

U.S. FDA approves Phase 3 Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma - Onco'Zine

Detected technologies

Overall confidence: 100%
Detected patterns
  • <link rel=["']stylesheet["'] [^>]+/wp-(?:content|includes)/
  • /wp-(?:content|includes)/

Overall confidence: 100%
Detected patterns
  • <!-- This site is optimized with the Yoast (?:WordPress )?SEO plugin v([\d.]+) -

Overall confidence: 100%
Detected patterns
  • googlesyndication\.com/

Overall confidence: 100%
Detected patterns
  • google-analytics\.com/(?:ga|urchin|analytics)\.js

Overall confidence: 100%
Detected patterns
  • <link[^>]* href=[^>]+fonts\.(?:googleapis|google)\.com

Overall confidence: 100%
Detected patterns
  • googletagmanager\.com/gtm\.js
  • googletagmanager\.com/gtag/js

Overall confidence: 100%
Detected patterns
  • cdn\.izooto\.\w+

Overall confidence: 100%
Detected patterns
  • mc\.yandex\.ru/metrika/(?:tag|watch)\.js

Overall confidence: 100%
Detected patterns
  • jquery.*\.js(?:\?ver(?:sion)?=([\d.]+))?

Overall confidence: 100%
Detected patterns
  • jquery[.-]migrate(?:-([\d.]+))?(?:\.min)?\.js(?:\?ver=([\d.]+))?

Page Statistics

112
Requests

90 %
HTTPS

54 %
IPv6

19
Domains

28
Subdomains

27
IPs

4
Countries

3104 kB
Transfer

7562 kB
Size

174
Cookies

Redirected requests

There were HTTP redirect chains for the following requests:

Request Chain 35
  • https://mc.yandex.ru/watch/96049782 HTTP 302
  • https://mc.yandex.ru/watch/96049782/1?redirnss=1
Request Chain 77
  • https://www.trustedsite.com/rpc/tmjs/oncozine.com/visit?rand=1712570848231 HTTP 302
  • https://www.trustedsite.com/rpc/tmjs/oncozine.com/visit?rand=1712570848231&hash=1712570848609

112 HTTP transactions

Resource
Path
Size
x-fer
Type
MIME-Type
Primary Request /
www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
242 KB
56 KB
Document
General
Full URL
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
0d7b49d0540f6c5dd3f429221e59cee58312cb95d78982abef9b3b446a817b66

Request headers

Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
accept-language
jp-JP,jp;q=0.9
sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
sec-ch-ua-mobile
?0
sec-ch-ua-platform
"Win32"

Response headers

content-encoding
gzip
content-type
text/html; charset=UTF-8
date
Mon, 08 Apr 2024 10:07:26 GMT
host-header
8441280b0c35cbc1147f8ba998a563a7
link
<https://www.oncozine.com/wp-json/>; rel="https://api.w.org/", <https://www.oncozine.com/wp-json/wp/v2/posts/14566>; rel="alternate"; type="application/json", <https://www.oncozine.com/?p=14566>; rel=shortlink
server
nginx
vary
Accept-Encoding
x-cache-enabled
True
x-cdn-c
all
x-httpd
1
x-proxy-cache
HIT
x-sg-cdn
1
siteground-optimizer-combined-css-3fa291f3a0a7cec83b2a65d2dc1fa74d.css
www.oncozine.com/wp-content/uploads/siteground-optimizer-assets/
912 KB
148 KB
Stylesheet
General
Full URL
https://www.oncozine.com/wp-content/uploads/siteground-optimizer-assets/siteground-optimizer-combined-css-3fa291f3a0a7cec83b2a65d2dc1fa74d.css
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
c99bf013d667b2880e2b75ad7cbb45c1a32d23abcf98c3bc9c58fb510fab9962

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:26 GMT
content-encoding
gzip
expires
Tue, 08 Apr 2025 01:23:13 GMT
last-modified
Wed, 22 Nov 2023 10:54:54 GMT
server
nginx
etag
W/"655dddfe-e40e7"
vary
Accept-Encoding
content-type
text/css
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
x-cdn-c
all
x-sg-cdn
1
js
www.googletagmanager.com/gtag/
240 KB
86 KB
Script
General
Full URL
https://www.googletagmanager.com/gtag/js?id=G-PGDBN4WRNY
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2404:6800:4004:81e::2008 , Australia, ASN15169 (GOOGLE, US),
Reverse DNS
Software
Google Tag Manager /
Resource Hash
725533309b1a62fed1e4995295791d9e6814fbafe2e36756fa27e9dafc825f6d
Security Headers
Name Value
Strict-Transport-Security max-age=31536000; includeSubDomains
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:26 GMT
content-encoding
br
strict-transport-security
max-age=31536000; includeSubDomains
server
Google Tag Manager
vary
Accept-Encoding
content-type
application/javascript; charset=UTF-8
access-control-allow-origin
*
cache-control
private, max-age=900
access-control-allow-credentials
true
cross-origin-resource-policy
cross-origin
access-control-allow-headers
Cache-Control
content-length
87463
x-xss-protection
0
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
expires
Mon, 08 Apr 2024 10:07:26 GMT
css
fonts.googleapis.com/
24 KB
2 KB
Stylesheet
General
Full URL
https://fonts.googleapis.com/css?family=Open+Sans%3A400%2C600%2C700%7CRoboto%3A400%2C500%2C700&display=swap&ver=12.2
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2404:6800:4004:821::200a , Australia, ASN15169 (GOOGLE, US),
Reverse DNS
Software
ESF /
Resource Hash
c338b0e3367bf7481fe8c1d97caf2af7b5e11702dabea1b234118678330581c8
Security Headers
Name Value
Strict-Transport-Security max-age=31536000
X-Content-Type-Options nosniff
X-Frame-Options SAMEORIGIN
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

strict-transport-security
max-age=31536000
date
Mon, 08 Apr 2024 10:07:26 GMT
content-encoding
gzip
x-content-type-options
nosniff
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
x-xss-protection
0
last-modified
Mon, 08 Apr 2024 09:59:16 GMT
server
ESF
cross-origin-opener-policy
same-origin-allow-popups
x-frame-options
SAMEORIGIN
content-type
text/css; charset=utf-8
access-control-allow-origin
*
cache-control
private, max-age=86400, stale-while-revalidate=604800
timing-allow-origin
*
link
<https://fonts.gstatic.com>; rel=preconnect; crossorigin
expires
Mon, 08 Apr 2024 10:07:26 GMT
frontend-gtag.min.js
www.oncozine.com/wp-content/plugins/google-analytics-premium/assets/js/
11 KB
4 KB
Script
General
Full URL
https://www.oncozine.com/wp-content/plugins/google-analytics-premium/assets/js/frontend-gtag.min.js?ver=8.25.0
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
d7bdba02afa8c04c13f280c71a50f8c8186c883711c5dabbd13566dd738bff0a

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:26 GMT
content-encoding
gzip
expires
Tue, 08 Apr 2025 00:45:15 GMT
last-modified
Wed, 06 Mar 2024 04:04:55 GMT
server
nginx
etag
W/"65e7eb67-2da9"
vary
Accept-Encoding
content-type
application/javascript
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
x-cdn-c
all
x-sg-cdn
1
trendmd.min.js
trendmd.s3.amazonaws.com/
161 KB
161 KB
Script
General
Full URL
https://trendmd.s3.amazonaws.com/trendmd.min.js?ver=6.5
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
HTTP/1.1
Security
TLS 1.3, , AES_128_GCM
Server
54.231.132.161 Ashburn, United States, ASN16509 (AMAZON-02, US),
Reverse DNS
s3-1-w.amazonaws.com
Software
AmazonS3 /
Resource Hash
a545ef0eb05fad4da777e169c844728471a17de62ae98b7c62bb746b658c9814

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

Date
Mon, 08 Apr 2024 10:07:27 GMT
Last-Modified
Thu, 21 Mar 2024 14:13:09 GMT
Server
AmazonS3
x-amz-request-id
H6A0TM5QXCW7QVDY
ETag
"5c6086bc50d7cba542be8f4c8b74d596"
x-amz-server-side-encryption
AES256
Content-Type
application/javascript
Accept-Ranges
bytes
Content-Length
164748
x-amz-id-2
l/BfSIyA0ETgqNt9bGyrOLicIhzalpfNphOCF21VQFdxKzXEjeBzEFjpxTNGifFTvN+d/ify7f0=
jquery.min.js
www.oncozine.com/wp-includes/js/jquery/
86 KB
35 KB
Script
General
Full URL
https://www.oncozine.com/wp-includes/js/jquery/jquery.min.js?ver=3.7.1
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
cb6f2d32c49d1c2b25e9ffc9aaafa3f83075346c01bcd4ae6eb187392a4292cf

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:26 GMT
content-encoding
gzip
expires
Tue, 08 Apr 2025 00:45:14 GMT
last-modified
Sun, 12 Nov 2023 05:05:50 GMT
server
nginx
etag
W/"65505d2e-15601"
vary
Accept-Encoding
content-type
application/javascript
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
x-cdn-c
all
x-sg-cdn
1
jquery-migrate.min.js
www.oncozine.com/wp-includes/js/jquery/
13 KB
5 KB
Script
General
Full URL
https://www.oncozine.com/wp-includes/js/jquery/jquery-migrate.min.js?ver=3.4.1
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
5274f11e6fb32ae0cf2dfb9f8043272865c397a7c4223b4cfa7d50ea52fbde89

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:26 GMT
content-encoding
gzip
expires
Tue, 08 Apr 2025 00:45:14 GMT
last-modified
Sat, 12 Aug 2023 07:28:06 GMT
server
nginx
etag
W/"64d73486-3509"
vary
Accept-Encoding
content-type
application/javascript
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
x-cdn-c
all
x-sg-cdn
1
cookie.min.js
www.oncozine.com/wp-content/uploads/siteground-optimizer-assets/
2 KB
1 KB
Script
General
Full URL
https://www.oncozine.com/wp-content/uploads/siteground-optimizer-assets/cookie.min.js?ver=3.14.1
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
c61b89fadbca6decaf2cec9a3b67d6117478667fa329c60ea1db79647dfc3c31

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:27 GMT
content-encoding
gzip
expires
Tue, 08 Apr 2025 01:23:15 GMT
last-modified
Sun, 16 May 2021 18:41:47 GMT
server
nginx
etag
W/"60a1676b-64e"
vary
Accept-Encoding
content-type
application/javascript
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
x-cdn-c
all
x-sg-cdn
1
adsbygoogle.js
pagead2.googlesyndication.com/pagead/js/
144 KB
50 KB
Script
General
Full URL
https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
216.58.220.130 , United States, ASN15169 (GOOGLE, US),
Reverse DNS
syd09s01-in-f130.1e100.net
Software
cafe /
Resource Hash
6572d1c36f0b5715eb6d6c38e8101ce7978d3eb752b7deb3c6afe91c50e08ad7
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:27 GMT
content-encoding
br
x-content-type-options
nosniff
p3p
policyref="https://www.googleadservices.com/pagead/p3p.xml", CP="NOI DEV PSA PSD IVA IVD OTP OUR OTR IND OTC"
cross-origin-resource-policy
cross-origin
content-disposition
attachment; filename="f.txt"
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
50825
x-xss-protection
0
server
cafe
etag
12130174887057408849
vary
Accept-Encoding
content-type
text/javascript; charset=UTF-8
access-control-allow-origin
*
cache-control
private, max-age=3600, stale-while-revalidate=3600
timing-allow-origin
*
link
<https://googleads.g.doubleclick.net>; rel="preconnect"; crossorigin
expires
Mon, 08 Apr 2024 10:07:27 GMT
amp-ad-0.1.js
cdn.ampproject.org/v0/
82 KB
24 KB
Script
General
Full URL
https://cdn.ampproject.org/v0/amp-ad-0.1.js
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2404:6800:4004:825::2001 , Australia, ASN15169 (GOOGLE, US),
Reverse DNS
Software
sffe /
Resource Hash
9d0e60a7060641ad5318dcfab49742f7fa71a203ade4b550107db279c2c45bd6
Security Headers
Name Value
Content-Security-Policy default-src * blob: data:; script-src blob: https://cdn.ampproject.org/lts/ https://cdn.ampproject.org/rtv/ https://cdn.ampproject.org/sw/ https://cdn.ampproject.org/v0.js https://cdn.ampproject.org/v0.mjs https://cdn.ampproject.org/v0/ https://cdn.ampproject.org/viewer/; object-src 'none'; style-src 'unsafe-inline' https://cdn.ampproject.org/rtv/ https://cdn.materialdesignicons.com https://cdnjs.cloudflare.com/ajax/libs/font-awesome/ https://cloud.typography.com https://fast.fonts.net https://fonts.googleapis.com https://maxcdn.bootstrapcdn.com https://p.typekit.net https://pro.fontawesome.com https://use.fontawesome.com https://use.typekit.net; report-uri https://csp.withgoogle.com/csp/amp
Strict-Transport-Security max-age=31536000; includeSubDomains; preload
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

content-security-policy
default-src * blob: data:; script-src blob: https://cdn.ampproject.org/lts/ https://cdn.ampproject.org/rtv/ https://cdn.ampproject.org/sw/ https://cdn.ampproject.org/v0.js https://cdn.ampproject.org/v0.mjs https://cdn.ampproject.org/v0/ https://cdn.ampproject.org/viewer/; object-src 'none'; style-src 'unsafe-inline' https://cdn.ampproject.org/rtv/ https://cdn.materialdesignicons.com https://cdnjs.cloudflare.com/ajax/libs/font-awesome/ https://cloud.typography.com https://fast.fonts.net https://fonts.googleapis.com https://maxcdn.bootstrapcdn.com https://p.typekit.net https://pro.fontawesome.com https://use.fontawesome.com https://use.typekit.net; report-uri https://csp.withgoogle.com/csp/amp
content-encoding
br
x-content-type-options
nosniff
date
Mon, 08 Apr 2024 10:07:27 GMT
strict-transport-security
max-age=31536000; includeSubDomains; preload
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
23137
x-xss-protection
0
server
sffe
etag
"6e09706846e2109e"
vary
Accept-Encoding
report-to
{"group":"amphtml-china-available","max_age":2592000,"endpoints":[{"url":"https://csp.withgoogle.com/csp/report-to/amphtml-china-available"}]}
content-type
text/javascript; charset=UTF-8
access-control-allow-origin
*
cache-control
private, max-age=604800, stale-while-revalidate=604800
accept-ranges
bytes
timing-allow-origin
*
cross-origin-opener-policy-report-only
same-origin; report-to="amphtml-china-available"
expires
Mon, 08 Apr 2024 10:07:27 GMT
/
secure.gdcstatic.com/
277 KB
104 KB
Script
General
Full URL
https://secure.gdcstatic.com/
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:3035::6815:1167 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
cd46134cb28e8255cbbb958d32436a83a04518c9f0910ab6ab1bfb64c8b803c3

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:26 GMT
content-encoding
br
cf-cache-status
DYNAMIC
nel
{"success_fraction":0,"report_to":"cf-nel","max_age":604800}
server
cloudflare
report-to
{"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=3XDaE3HRrhCpGTqGC4XLr%2Fe50fZFoHEMNDBTw1DWVJ15TuiyarD4h0pcOL8M08bja44v%2BlaX%2BHeM5xl%2BAhNi1BN%2F3gczeQppIt%2FNBCMcfmFKc6puc3wFX18HIokeDgkKXOtg7Ba4guDKmPY2Gz665ef3lw%3D%3D"}],"group":"cf-nel","max_age":604800}
content-type
application/javascript; charset=UTF-8
cf-ray
8711734d9cf9af46-NRT
alt-svc
h3=":443"; ma=86400
oncozine_270x90.png
www.oncozine.com/wp-content/uploads/2019/06/
4 KB
5 KB
Image
General
Full URL
https://www.oncozine.com/wp-content/uploads/2019/06/oncozine_270x90.png
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
f26df9247b81fa6d3832bf203841b18b416d000eb716aa11a3782062002ff1ab

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:26 GMT
expires
Sun, 06 Apr 2025 12:50:57 GMT
last-modified
Fri, 28 Jun 2019 07:11:16 GMT
server
nginx
etag
"5d15bd94-113b"
content-type
image/png
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
accept-ranges
bytes
content-length
4411
x-cdn-c
all
x-sg-cdn
1
stjude_finding-cures_ashtyn_webstatic_728x90.jpg
www.oncozine.com/wp-content/uploads/2023/11/
47 KB
48 KB
Image
General
Full URL
https://www.oncozine.com/wp-content/uploads/2023/11/stjude_finding-cures_ashtyn_webstatic_728x90.jpg
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
fb81fc1f338a3cdbd4cbe7a9305770e55b3f6a06cbd187cc9081cdcd29fed0dc

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:26 GMT
expires
Fri, 04 Apr 2025 06:38:30 GMT
last-modified
Tue, 14 Nov 2023 00:12:53 GMT
server
nginx
etag
"6552bb85-bd71"
content-type
image/jpeg
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
accept-ranges
bytes
content-length
48497
x-cdn-c
all
x-sg-cdn
1
oncozine_brief-download.png
www.oncozine.com/wp-content/uploads/2019/04/
57 KB
57 KB
Image
General
Full URL
https://www.oncozine.com/wp-content/uploads/2019/04/oncozine_brief-download.png
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
6eb6184efb448222f0fb01fb8965fc3500a50e36f8c76a4a8c2de9d9450834da

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:26 GMT
expires
Fri, 04 Apr 2025 06:38:30 GMT
last-modified
Fri, 28 Jun 2019 07:12:07 GMT
server
nginx
etag
"5d15bdc7-e32f"
content-type
image/png
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
accept-ranges
bytes
content-length
58159
x-cdn-c
all
x-sg-cdn
1
oncozine-140x48_wht.png
www.oncozine.com/wp-content/uploads/2019/06/
2 KB
2 KB
Image
General
Full URL
https://www.oncozine.com/wp-content/uploads/2019/06/oncozine-140x48_wht.png
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
bdd7412a7c00669a80542cd494bb200ed6a57cfd7ff0158ce6ae416b98acbd1f

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:27 GMT
expires
Fri, 04 Apr 2025 06:38:31 GMT
last-modified
Fri, 28 Jun 2019 07:11:12 GMT
server
nginx
etag
"5d15bd90-878"
content-type
image/png
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
accept-ranges
bytes
content-length
2168
x-cdn-c
all
x-sg-cdn
1
Mantle_cell_lymphoma-scaled.jpg
www.oncozine.com/wp-content/uploads/2020/03/
624 KB
625 KB
Image
General
Full URL
https://www.oncozine.com/wp-content/uploads/2020/03/Mantle_cell_lymphoma-scaled.jpg
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
a90c8ed089c48a8cc67d58559fcfcdea58cea67b12d38d448a080bd624ffd265

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:26 GMT
expires
Tue, 08 Apr 2025 06:29:43 GMT
last-modified
Fri, 06 Mar 2020 19:44:54 GMT
server
nginx
etag
"5e62a836-9c03a"
content-type
image/jpeg
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
accept-ranges
bytes
content-length
639034
x-cdn-c
all
x-sg-cdn
1
OZ-white_150x150.jpg
www.oncozine.com/wp-content/uploads/2019/11/
8 KB
8 KB
Image
General
Full URL
https://www.oncozine.com/wp-content/uploads/2019/11/OZ-white_150x150.jpg
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
b7817c2d04d6c82cf1a28d541d0575136d67ddd68f855a26e60fc7ab17dcba09

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:27 GMT
expires
Mon, 07 Apr 2025 08:31:27 GMT
last-modified
Wed, 27 Nov 2019 00:11:55 GMT
server
nginx
etag
"5dddbf4b-1e7b"
content-type
image/jpeg
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
accept-ranges
bytes
content-length
7803
x-cdn-c
all
x-sg-cdn
1
trendmd.min.js
js.trendmd.com/
161 KB
41 KB
Script
General
Full URL
https://js.trendmd.com/trendmd.min.js
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
172.67.159.150 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
a545ef0eb05fad4da777e169c844728471a17de62ae98b7c62bb746b658c9814

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:27 GMT
content-encoding
br
cf-cache-status
HIT
last-modified
Thu, 21 Mar 2024 10:53:34 GMT
nel
{"success_fraction":0,"report_to":"cf-nel","max_age":604800}
server
cloudflare
age
40680
etag
W/"65fc11ae-2838c"
vary
Accept-Encoding
report-to
{"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=d0pe3Ke4AKIYsZl%2FoeLH25krPd9zD30msGM2v6GNb%2BwbQhoVdFmw%2B%2BCWavuSgFAWRRfJ2mO1OalpWqfnmzinNmXPseLMUJRjANJ93UE1Urljl65hgD2u148El5T%2BLecPRg%3D%3D"}],"group":"cf-nel","max_age":604800}
content-type
application/javascript; charset=UTF-8
access-control-allow-origin
*
cache-control
public, max-age=86400, must-revalidate
cf-ray
87117354fa58f609-NRT
alt-svc
h3=":443"; ma=86400
rss.png
www.oncozine.com/wp-includes/images/
608 B
864 B
Image
General
Full URL
https://www.oncozine.com/wp-includes/images/rss.png
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
0c6daa646e0a867e5f721b5017c98cfd2c82c26c60b614531ddae8a5d9986be8

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:27 GMT
expires
Sun, 06 Apr 2025 12:50:58 GMT
last-modified
Thu, 27 Jun 2019 00:15:07 GMT
server
nginx
etag
"5d140a8b-260"
content-type
image/png
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
accept-ranges
bytes
content-length
608
x-cdn-c
all
x-sg-cdn
1
oncozine_270x90_wht.png
www.oncozine.com/wp-content/uploads/2019/06/
4 KB
5 KB
Image
General
Full URL
https://www.oncozine.com/wp-content/uploads/2019/06/oncozine_270x90_wht.png
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
13997b0590d8f569c9fba73566c6ba0dceb10dbec18a5315fe2e5f5e30ce86f5

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:27 GMT
expires
Mon, 07 Apr 2025 02:51:49 GMT
last-modified
Fri, 28 Jun 2019 07:11:14 GMT
server
nginx
etag
"5d15bd92-1117"
content-type
image/png
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
accept-ranges
bytes
content-length
4375
x-cdn-c
all
x-sg-cdn
1
infolinks_main.js
resources.infolinks.com/js/
4 KB
3 KB
Script
General
Full URL
https://resources.infolinks.com/js/infolinks_main.js
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.2, ECDHE_ECDSA, AES_128_GCM
Server
172.66.42.247 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
aae9c69e350c53a164f39e3dd9a338a11728ad5fecbc1ea150bfc1058d2d2c79

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:26 GMT
via
1.1 google
content-encoding
gzip
cf-cache-status
HIT
last-modified
Wed, 03 Apr 2024 09:01:30 GMT
server
cloudflare
age
3906
etag
W/"10d9-6152d77f774ca"
vary
Accept-Encoding
content-type
application/javascript
cache-control
max-age=3600
cf-ray
8711734dff336848-NRT
expires
Mon, 08 Apr 2024 10:02:20 GMT
subcription-popup.png
www.oncozine.com/wp-content/uploads/2021/05/
73 KB
73 KB
Image
General
Full URL
https://www.oncozine.com/wp-content/uploads/2021/05/subcription-popup.png
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
e9e16fec38358608c89c9f27bb8f48ad326601b937da8ceea9ecd15df4b0467b

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:27 GMT
expires
Sun, 06 Apr 2025 12:50:58 GMT
last-modified
Sun, 16 May 2021 18:56:43 GMT
server
nginx
etag
"60a16aeb-12447"
content-type
image/png
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
accept-ranges
bytes
content-length
74823
x-cdn-c
all
x-sg-cdn
1
adrotate-dyngroup.min.js
www.oncozine.com/wp-content/uploads/siteground-optimizer-assets/
931 B
818 B
Script
General
Full URL
https://www.oncozine.com/wp-content/uploads/siteground-optimizer-assets/adrotate-dyngroup.min.js
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
5f48395a7ac829a7167071efac8158ff44db1d95bc2394cf0c3f5ecec4456cf4

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:27 GMT
content-encoding
gzip
expires
Tue, 08 Apr 2025 00:45:15 GMT
last-modified
Wed, 25 Dec 2019 04:41:51 GMT
server
nginx
etag
W/"5e02e88f-3a3"
vary
Accept-Encoding
content-type
application/javascript
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
x-cdn-c
all
x-sg-cdn
1
lazysizes.min.js
www.oncozine.com/wp-content/plugins/sg-cachepress/assets/js/
8 KB
4 KB
Script
General
Full URL
https://www.oncozine.com/wp-content/plugins/sg-cachepress/assets/js/lazysizes.min.js?ver=7.5.0
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
cb34d2ee2a93fd11b734c124a6fc661339585c63382d08eb31bf921b66519eac

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:27 GMT
content-encoding
gzip
expires
Tue, 08 Apr 2025 01:23:15 GMT
last-modified
Thu, 21 Mar 2024 13:58:07 GMT
server
nginx
etag
W/"65fc3cef-1ed0"
vary
Accept-Encoding
content-type
application/javascript
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
x-cdn-c
all
x-sg-cdn
1
script.min.js
www.oncozine.com/wp-content/plugins/wp-job-openings/assets/js/
48 KB
18 KB
Script
General
Full URL
https://www.oncozine.com/wp-content/plugins/wp-job-openings/assets/js/script.min.js?ver=3.4.5
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
f5c4ba1964e745443a0c654fc82f22e7e540e84da7c72d20ea85451cc79a035a

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:27 GMT
content-encoding
gzip
expires
Tue, 08 Apr 2025 00:45:15 GMT
last-modified
Fri, 29 Mar 2024 21:33:04 GMT
server
nginx
etag
W/"66073390-be7c"
vary
Accept-Encoding
content-type
application/javascript
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
x-cdn-c
all
x-sg-cdn
1
gtm4wp-form-move-tracker.min.js
www.oncozine.com/wp-content/uploads/siteground-optimizer-assets/
1 KB
591 B
Script
General
Full URL
https://www.oncozine.com/wp-content/uploads/siteground-optimizer-assets/gtm4wp-form-move-tracker.min.js?ver=1.20.1
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
8cea0555dc188f24cff6d8baccdec6cf8794420a9112801c295797d767cc39de

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:27 GMT
content-encoding
gzip
expires
Tue, 08 Apr 2025 00:45:15 GMT
last-modified
Fri, 29 Mar 2024 21:31:33 GMT
server
nginx
etag
W/"66073335-471"
vary
Accept-Encoding
content-type
application/javascript
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
x-cdn-c
all
x-sg-cdn
1
tagdiv_theme.min.js
www.oncozine.com/wp-content/plugins/td-composer/legacy/Newspaper/js/
301 KB
87 KB
Script
General
Full URL
https://www.oncozine.com/wp-content/plugins/td-composer/legacy/Newspaper/js/tagdiv_theme.min.js?ver=12.2
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
7ab56986ff9a66c35dcce1d3e2e2991e562a690e4e9d7388ea94f107cf49393f

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:27 GMT
content-encoding
gzip
expires
Tue, 08 Apr 2025 01:23:15 GMT
last-modified
Mon, 09 Jan 2023 15:02:14 GMT
server
nginx
etag
W/"63bc2c76-4b207"
vary
Accept-Encoding
content-type
application/javascript
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
x-cdn-c
all
x-sg-cdn
1
comment-reply.min.js
www.oncozine.com/wp-includes/js/
3 KB
2 KB
Script
General
Full URL
https://www.oncozine.com/wp-includes/js/comment-reply.min.js?ver=6.5
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
e174a58a503ab84b3d1b9de12fd3895788204485170f1289e445f7b5b98ec789

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:27 GMT
content-encoding
gzip
expires
Tue, 08 Apr 2025 01:23:15 GMT
last-modified
Tue, 07 Jun 2022 15:54:11 GMT
server
nginx
etag
W/"629f74a3-ba5"
vary
Accept-Encoding
content-type
application/javascript
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
x-cdn-c
all
x-sg-cdn
1
child-js.min.js
www.oncozine.com/wp-content/uploads/siteground-optimizer-assets/
274 B
461 B
Script
General
Full URL
https://www.oncozine.com/wp-content/uploads/siteground-optimizer-assets/child-js.min.js?ver=85bc226dad90946a0a8a7e2ed033c0f6
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
8513b83f01128609053a66efcd20696261ae6b3d7b4a2df81f1ebde7a28f1544

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:27 GMT
content-encoding
gzip
expires
Tue, 08 Apr 2025 01:23:15 GMT
last-modified
Sun, 16 May 2021 21:24:04 GMT
server
nginx
etag
W/"60a18d74-112"
vary
Accept-Encoding
content-type
application/javascript
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
x-cdn-c
all
x-sg-cdn
1
31f2e0ece29b1c721db3d27d9d0230c2b049abcf.js
cdn.izooto.com/scripts/
1 KB
847 B
Script
General
Full URL
https://cdn.izooto.com/scripts/31f2e0ece29b1c721db3d27d9d0230c2b049abcf.js?ver=3.7.16
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700::6812:d841 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
4e0b90ad65c1ab4ea2aabdb66f782bed2a72629a2624d9b9ee46bfa886a83852
Security Headers
Name Value
X-Xss-Protection 1; mode=block

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:26 GMT
content-encoding
br
cf-cache-status
HIT
cf-bgj
minify
last-modified
Mon, 01 Jul 2019 07:41:53 GMT
server
cloudflare
age
73460
etag
W/"5d19b941-40b"
vary
Accept-Encoding
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=1382400
cf-ray
8711734dfabeaf87-NRT
x-xss-protection
1; mode=block
expires
Wed, 24 Apr 2024 10:07:26 GMT
wpforms-user-journey.min.js
www.oncozine.com/wp-content/plugins/wpforms-user-journey/assets/js/
2 KB
1 KB
Script
General
Full URL
https://www.oncozine.com/wp-content/plugins/wpforms-user-journey/assets/js/wpforms-user-journey.min.js?ver=1.2.0
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
767ba5dac6e8ff3f5f1e3a953bacc178069559b76ea24341cb3eebcb8f1d4470

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:26 GMT
content-encoding
gzip
expires
Tue, 08 Apr 2025 00:45:14 GMT
last-modified
Fri, 29 Mar 2024 21:34:24 GMT
server
nginx
etag
W/"660733e0-66b"
vary
Accept-Encoding
content-type
application/javascript
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
x-cdn-c
all
x-sg-cdn
1
gtm.js
www.googletagmanager.com/
203 KB
73 KB
Script
General
Full URL
https://www.googletagmanager.com/gtm.js?id=GTM-T5CT8SP
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2404:6800:4004:81e::2008 , Australia, ASN15169 (GOOGLE, US),
Reverse DNS
Software
Google Tag Manager /
Resource Hash
0e5a75eee46982df9962d95183829f9cdb960133786f71fd3cc7683e0b31ee26
Security Headers
Name Value
Strict-Transport-Security max-age=31536000; includeSubDomains
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:27 GMT
content-encoding
br
strict-transport-security
max-age=31536000; includeSubDomains
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
74452
x-xss-protection
0
last-modified
Mon, 08 Apr 2024 09:00:00 GMT
server
Google Tag Manager
vary
Accept-Encoding
content-type
application/javascript; charset=UTF-8
access-control-allow-origin
*
cache-control
private, max-age=900
access-control-allow-credentials
true
access-control-allow-headers
Cache-Control
expires
Mon, 08 Apr 2024 10:07:27 GMT
js
www.googletagmanager.com/gtag/
198 KB
72 KB
Script
General
Full URL
https://www.googletagmanager.com/gtag/js?id=UA-188673758-1&l=dataLayer&cx=c
Requested by
Host: www.googletagmanager.com
URL: https://www.googletagmanager.com/gtag/js?id=G-PGDBN4WRNY
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2404:6800:4004:81e::2008 , Australia, ASN15169 (GOOGLE, US),
Reverse DNS
Software
Google Tag Manager /
Resource Hash
aa518031f647889e73a5f90e762c42f1de3ad1d0106205f8927a58925fa97e46
Security Headers
Name Value
Strict-Transport-Security max-age=31536000; includeSubDomains
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:27 GMT
content-encoding
br
strict-transport-security
max-age=31536000; includeSubDomains
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
73391
x-xss-protection
0
last-modified
Mon, 08 Apr 2024 09:00:00 GMT
server
Google Tag Manager
vary
Accept-Encoding
content-type
application/javascript; charset=UTF-8
access-control-allow-origin
*
cache-control
private, max-age=900
access-control-allow-credentials
true
access-control-allow-headers
Cache-Control
expires
Mon, 08 Apr 2024 10:07:27 GMT
collect
www.google-analytics.com/g/
0
255 B
Ping
General
Full URL
https://www.google-analytics.com/g/collect?v=2&tid=G-PGDBN4WRNY&gtm=45je4430v876608970za200&_p=1712570846381&gcd=13l3l3l3l1&npa=0&dma=0&gdid=dZGIzZG&cid=227320689.1712570847&ul=en-us&sr=800x600&uaa=x86&uab=64&uafvl=Google%2520Chrome%3B123.0.6312.105%7CNot%253AA-Brand%3B8.0.0.0%7CChromium%3B123.0.6312.105&uamb=0&uam=&uap=Win32&uapv=10.0.0&uaw=0&pscdl=noapi&_s=1&dp=%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&sid=1712570846&sct=1&seg=0&dl=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&dt=U.S.%20FDA%20approves%20Phase%203%20Study%20Design%20for%20Zilovertamab%20in%20the%20Treatment%20of%20Mantle%20Cell%20Lymphoma%20-%20Onco%27Zine&en=page_view&_fv=1&_nsi=1&_ss=1&_ee=1&ep.allow_anchor=true&ep.forceSSL=true&ep.anonymize_ip=true&epn.site_speed_sample_rate=5&tfd=488
Requested by
Host: www.googletagmanager.com
URL: https://www.googletagmanager.com/gtag/js?id=G-PGDBN4WRNY
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2404:6800:4004:80b::200e , Australia, ASN15169 (GOOGLE, US),
Reverse DNS
Software
Golfe2 /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

pragma
no-cache
date
Mon, 08 Apr 2024 10:07:26 GMT
server
Golfe2
content-type
text/plain
access-control-allow-origin
https://www.oncozine.com
cache-control
no-cache, no-store, must-revalidate
access-control-allow-credentials
true
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
0
expires
Fri, 01 Jan 1990 00:00:00 GMT
tag.js
mc.yandex.ru/metrika/
224 KB
77 KB
Script
General
Full URL
https://mc.yandex.ru/metrika/tag.js
Requested by
Host: secure.gdcstatic.com
URL: https://secure.gdcstatic.com/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
2a02:6b8::1:119 , Russian Federation, ASN13238 (YANDEX, RU),
Reverse DNS
Software
/
Resource Hash
3e0311605837ecf0c1dd99a5f275766847d702959e40ec6f98b08128d11e474c
Security Headers
Name Value
Strict-Transport-Security max-age=31536000

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:28 GMT
content-encoding
br
strict-transport-security
max-age=31536000
last-modified
Fri, 05 Apr 2024 08:05:36 GMT
accept-ch
Sec-CH-UA-Bitness, Sec-CH-UA-Arch, Sec-CH-UA-Full-Version, Sec-CH-UA-Mobile, Sec-CH-UA-Model, Sec-CH-UA-Platform-Version, Sec-CH-UA-Full-Version-List, Sec-CH-UA-Platform, Sec-CH-UA, UA-Bitness, UA-Arch, UA-Full-Version, UA-Mobile, UA-Model, UA-Platform-Version, UA-Platform, UA
etag
"660fb0d0-132c6"
content-type
application/javascript
access-control-allow-origin
*
cache-control
max-age=3600
timing-allow-origin
*
content-length
78534
expires
Mon, 08 Apr 2024 11:07:28 GMT
1
mc.yandex.ru/watch/96049782/
Redirect Chain
  • https://mc.yandex.ru/watch/96049782
  • https://mc.yandex.ru/watch/96049782/1?redirnss=1
43 B
202 B
Image
General
Full URL
https://mc.yandex.ru/watch/96049782/1?redirnss=1
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Server
2a02:6b8::1:119 , Russian Federation, ASN13238 (YANDEX, RU),
Reverse DNS
Software
/
Resource Hash
548f2d6f4d0d820c6c5ffbeffcbd7f0e73193e2932eefe542accc84762deec87
Security Headers
Name Value
Strict-Transport-Security max-age=31536000
X-Xss-Protection 1; mode=block

Request headers

accept-language
jp-JP,jp;q=0.9
Referer
https://www.oncozine.com/
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36

Response headers

pragma
no-cache
date
Mon, 08 Apr 2024 10:07:28 GMT
strict-transport-security
max-age=31536000
last-modified
Mon, 08-Apr-2024 10:07:28 GMT
accept-ch
Sec-CH-UA-Bitness, Sec-CH-UA-Arch, Sec-CH-UA-Full-Version, Sec-CH-UA-Mobile, Sec-CH-UA-Model, Sec-CH-UA-Platform-Version, Sec-CH-UA-Full-Version-List, Sec-CH-UA-Platform, Sec-CH-UA, UA-Bitness, UA-Arch, UA-Full-Version, UA-Mobile, UA-Model, UA-Platform-Version, UA-Platform, UA
content-type
image/gif
cache-control
private, no-cache, no-store, must-revalidate, max-age=0
content-length
43
x-xss-protection
1; mode=block
expires
Mon, 08-Apr-2024 10:07:28 GMT

Redirect headers

pragma
no-cache
date
Mon, 08 Apr 2024 10:07:28 GMT
strict-transport-security
max-age=31536000
last-modified
Mon, 08-Apr-2024 10:07:28 GMT
accept-ch
Sec-CH-UA-Bitness, Sec-CH-UA-Arch, Sec-CH-UA-Full-Version, Sec-CH-UA-Mobile, Sec-CH-UA-Model, Sec-CH-UA-Platform-Version, Sec-CH-UA-Full-Version-List, Sec-CH-UA-Platform, Sec-CH-UA, UA-Bitness, UA-Arch, UA-Full-Version, UA-Mobile, UA-Model, UA-Platform-Version, UA-Platform, UA
location
/watch/96049782/1?redirnss=1
cache-control
private, no-cache, no-store, must-revalidate, max-age=0
x-xss-protection
1; mode=block
expires
Mon, 08-Apr-2024 10:07:28 GMT
like.php
www.facebook.com/plugins/ Frame D45C
0
0
Document
General
Full URL
https://www.facebook.com/plugins/like.php?href=https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/&layout=button_count&show_faces=false&width=105&action=like&colorscheme=light&height=21
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a03:2880:f10f:83:face:b00c:0:25de Tokyo, Japan, ASN32934 (FACEBOOK, US),
Reverse DNS
Software
/
Resource Hash
Security Headers
Name Value
Content-Security-Policy default-src data: blob: 'self' https://*.fbsbx.com 'unsafe-inline' *.facebook.com *.fbcdn.net 'unsafe-eval';script-src *.facebook.com *.fbcdn.net *.facebook.net 127.0.0.1:* 'unsafe-inline' blob: data: 'self' connect.facebook.net 'unsafe-eval' https://*.google-analytics.com *.google.com;style-src *.fbcdn.net data: *.facebook.com 'unsafe-inline' https://fonts.googleapis.com;connect-src *.facebook.com facebook.com *.fbcdn.net *.facebook.net wss://*.facebook.com:* wss://*.whatsapp.com:* wss://*.fbcdn.net attachment.fbsbx.com ws://localhost:* blob: *.cdninstagram.com 'self' http://localhost:3103 wss://gateway.facebook.com wss://edge-chat.facebook.com wss://snaptu-d.facebook.com wss://kaios-d.facebook.com/ v.whatsapp.net *.fbsbx.com *.fb.com https://*.google-analytics.com;font-src data: *.facebook.com *.fbcdn.net *.fbsbx.com https://fonts.gstatic.com;img-src *.fbcdn.net *.facebook.com data: https://*.fbsbx.com facebook.com *.cdninstagram.com fbsbx.com fbcdn.net connect.facebook.net *.carriersignal.info blob: android-webview-video-poster: *.whatsapp.net *.fb.com *.oculuscdn.com *.tenor.co *.tenor.com *.giphy.com https://www.googleadservices.com https://googleads.g.doubleclick.net https://*.google-analytics.com;media-src *.cdninstagram.com blob: *.fbcdn.net *.fbsbx.com www.facebook.com *.facebook.com data: *.tenor.co *.tenor.com https://*.giphy.com;frame-src *.facebook.com *.fbsbx.com fbsbx.com data: www.instagram.com *.fbcdn.net https://paywithmybank.com/ https://sandbox.paywithmybank.com/ https://www.googleadservices.com https://googleads.g.doubleclick.net https://www.google.com https://td.doubleclick.net *.google.com *.doubleclick.net;worker-src blob: *.facebook.com data: https://*.google-analytics.com *.google.com;block-all-mixed-content;upgrade-insecure-requests;
Strict-Transport-Security max-age=15552000; preload
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Referer
https://www.oncozine.com/
Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
accept-language
jp-JP,jp;q=0.9
sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
sec-ch-ua-mobile
?0
sec-ch-ua-platform
"Win32"

Response headers

alt-svc
h3=":443"; ma=86400
cache-control
private, no-cache, no-store, must-revalidate
content-encoding
zstd
content-security-policy
default-src data: blob: 'self' https://*.fbsbx.com 'unsafe-inline' *.facebook.com *.fbcdn.net 'unsafe-eval';script-src *.facebook.com *.fbcdn.net *.facebook.net 127.0.0.1:* 'unsafe-inline' blob: data: 'self' connect.facebook.net 'unsafe-eval' https://*.google-analytics.com *.google.com;style-src *.fbcdn.net data: *.facebook.com 'unsafe-inline' https://fonts.googleapis.com;connect-src *.facebook.com facebook.com *.fbcdn.net *.facebook.net wss://*.facebook.com:* wss://*.whatsapp.com:* wss://*.fbcdn.net attachment.fbsbx.com ws://localhost:* blob: *.cdninstagram.com 'self' http://localhost:3103 wss://gateway.facebook.com wss://edge-chat.facebook.com wss://snaptu-d.facebook.com wss://kaios-d.facebook.com/ v.whatsapp.net *.fbsbx.com *.fb.com https://*.google-analytics.com;font-src data: *.facebook.com *.fbcdn.net *.fbsbx.com https://fonts.gstatic.com;img-src *.fbcdn.net *.facebook.com data: https://*.fbsbx.com facebook.com *.cdninstagram.com fbsbx.com fbcdn.net connect.facebook.net *.carriersignal.info blob: android-webview-video-poster: *.whatsapp.net *.fb.com *.oculuscdn.com *.tenor.co *.tenor.com *.giphy.com https://www.googleadservices.com https://googleads.g.doubleclick.net https://*.google-analytics.com;media-src *.cdninstagram.com blob: *.fbcdn.net *.fbsbx.com www.facebook.com *.facebook.com data: *.tenor.co *.tenor.com https://*.giphy.com;frame-src *.facebook.com *.fbsbx.com fbsbx.com data: www.instagram.com *.fbcdn.net https://paywithmybank.com/ https://sandbox.paywithmybank.com/ https://www.googleadservices.com https://googleads.g.doubleclick.net https://www.google.com https://td.doubleclick.net *.google.com *.doubleclick.net;worker-src blob: *.facebook.com data: https://*.google-analytics.com *.google.com;block-all-mixed-content;upgrade-insecure-requests;
content-type
text/html; charset="utf-8"
cross-origin-embedder-policy-report-only
require-corp;report-to="coep_report"
cross-origin-opener-policy
unsafe-none;report-to="coop_report"
cross-origin-resource-policy
cross-origin
date
Mon, 08 Apr 2024 10:07:27 GMT
document-policy
force-load-at-top
expires
Sat, 01 Jan 2000 00:00:00 GMT
origin-agent-cluster
?0
permissions-policy
accelerometer=(), attribution-reporting=(self), autoplay=(), bluetooth=(), camera=(self), ch-device-memory=(), ch-downlink=(), ch-ect=(), ch-rtt=(), ch-save-data=(), ch-ua-arch=(), ch-ua-bitness=(), clipboard-read=(self), clipboard-write=(self), display-capture=(self), encrypted-media=(self), fullscreen=(self), gamepad=*, geolocation=(self), gyroscope=(), hid=(), idle-detection=(), keyboard-map=(), local-fonts=(), magnetometer=(), microphone=(self), midi=(), otp-credentials=(), payment=(), picture-in-picture=(self), publickey-credentials-get=(self), screen-wake-lock=(), serial=(), usb=(), window-management=(), xr-spatial-tracking=(self);report-to="permissions_policy"
pragma
no-cache
report-to
{"max_age":2592000,"endpoints":[{"url":"https:\/\/www.facebook.com\/browser_reporting\/coop\/?minimize=0"}],"group":"coop_report","include_subdomains":true}, {"max_age":86400,"endpoints":[{"url":"https:\/\/www.facebook.com\/browser_reporting\/coep\/?minimize=0"}],"group":"coep_report"}, {"max_age":259200,"endpoints":[{"url":"https:\/\/www.facebook.com\/ajax\/browser_error_reports\/?device_level=unknown"}]}, {"max_age":21600,"endpoints":[{"url":"https:\/\/www.facebook.com\/ajax\/browser_error_reports\/"}],"group":"permissions_policy"}
reporting-endpoints
coop_report="https://www.facebook.com/browser_reporting/coop/?minimize=0", coep_report="https://www.facebook.com/browser_reporting/coep/?minimize=0", default="https://www.facebook.com/ajax/browser_error_reports/?device_level=unknown", permissions_policy="https://www.facebook.com/ajax/browser_error_reports/"
strict-transport-security
max-age=15552000; preload
vary
Accept-Encoding
x-content-type-options
nosniff
x-fb-connection-quality
EXCELLENT; q=0.9, rtt=1, rtx=0, c=10, mss=1294, tbw=2799, tp=-1, tpl=-1, uplat=271, ullat=0
x-fb-debug
azrFV49R4zzjAGDCkIt5h/T+9gjgQMeCWZ2r1loRn68Apj1gfTSpS0Twjxl+/xmiqiWrrUjLSxzhHc/Pk1N0lw==
x-xss-protection
0
truncated
/
42 B
0
Image
General
Full URL
data:truncated
Protocol
DATA
Server
-, , ASN (),
Reverse DNS
Software
/
Resource Hash
ef1955ae757c8b966c83248350331bd3a30f658ced11f387f8ebf05ab3368629

Request headers

accept-language
jp-JP,jp;q=0.9
Referer
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36

Response headers

Content-Type
image/gif
truncated
/
111 B
0
Image
General
Full URL
data:truncated
Protocol
DATA
Server
-, , ASN (),
Reverse DNS
Software
/
Resource Hash
7ae5b52b01b37efb4547c3493f75abf51dc034326bb6f1ff6fc97348065716ba

Request headers

accept-language
jp-JP,jp;q=0.9
Referer
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36

Response headers

Content-Type
image/png
1.js
cdn.ywxi.net/js/
20 KB
6 KB
Script
General
Full URL
https://cdn.ywxi.net/js/1.js
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2600:9000:2157:e400:14:6bfc:5740:93a1 , United States, ASN16509 (AMAZON-02, US),
Reverse DNS
Software
Apache /
Resource Hash
9c1ea67c36d8b7c7531a6bbc78879cdfb4d3bfe22ee52a4e48c82c78f2d30a78
Security Headers
Name Value
Strict-Transport-Security max-age=31536000; includeSubDomains
X-Content-Type-Options nosniff

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 09:39:47 GMT
strict-transport-security
max-age=31536000; includeSubDomains
x-content-type-options
nosniff
content-encoding
gzip
via
1.1 2402083883f8d7e887ab58fb56e109ac.cloudfront.net (CloudFront)
x-amz-cf-pop
NRT12-C3
age
1660
content-security-policy-report-only
report-uri https://52723791ca12811bfedec52ea4c44290.report-uri.com/r/d/csp/reportOnly; default-src 'self'; script-src * 'unsafe-inline' 'unsafe-eval'; script-src-elem * 'unsafe-inline'; script-src-attr 'unsafe-inline'; style-src 'self' 'unsafe-inline'; style-src-elem * 'unsafe-inline'; style-src-attr 'self' 'unsafe-inline'; img-src * data:; font-src * data:; connect-src *; media-src * blob:; object-src 'none'; frame-src *; frame-ancestors *; form-action 'self'
x-cache
Hit from cloudfront
content-length
4887
referrer-policy
strict-origin-when-cross-origin
server
Apache
content-type
text/javascript; charset=utf-8
access-control-allow-origin
*
x-amz-cf-id
tRZDxRyMoyJlNgLqWHaBy4l_TLFxuPnU5lZRwxz7AMjwpVp5OU6OJw==
expires
Mon, 08 Apr 2024 10:39:47 GMT
ice.js
resources.infolinks.com/js/1928.005-3.034/
189 KB
58 KB
Script
General
Full URL
https://resources.infolinks.com/js/1928.005-3.034/ice.js
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.2, ECDHE_ECDSA, AES_128_GCM
Server
172.66.42.247 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
3b7c674a82f8a947fc5a891870aa6e78930e7fe3533793921af870854bc0bf00

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:27 GMT
via
1.1 google
content-encoding
gzip
cf-cache-status
HIT
last-modified
Tue, 02 Apr 2024 06:51:09 GMT
server
cloudflare
age
10385
etag
W/"2f3ac-6151787f58a80"
vary
Accept-Encoding
content-type
application/javascript
cache-control
max-age=2592000
cf-ray
87117354ee8d6848-NRT
expires
Wed, 08 May 2024 07:14:22 GMT
truncated
/
121 B
0
Image
General
Full URL
data:truncated
Protocol
DATA
Server
-, , ASN (),
Reverse DNS
Software
/
Resource Hash
a4b423bd3e84385d2bb624a55cddfaafe863235df9791628cb4fc0a9472d3f76

Request headers

accept-language
jp-JP,jp;q=0.9
Referer
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36

Response headers

Content-Type
image/png
newspaper.woff
www.oncozine.com/wp-content/themes/Newspaper/images/icons/
33 KB
33 KB
Font
General
Full URL
https://www.oncozine.com/wp-content/themes/Newspaper/images/icons/newspaper.woff?221
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/wp-content/uploads/siteground-optimizer-assets/siteground-optimizer-combined-css-3fa291f3a0a7cec83b2a65d2dc1fa74d.css
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
d2054b9fb412f742d8d13aa75a48e59b830094999f9000ae8c69916e11b8d805

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/wp-content/uploads/siteground-optimizer-assets/siteground-optimizer-combined-css-3fa291f3a0a7cec83b2a65d2dc1fa74d.css
Origin
https://www.oncozine.com
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:27 GMT
expires
Sun, 06 Apr 2025 12:50:59 GMT
last-modified
Mon, 09 Jan 2023 15:02:05 GMT
server
nginx
etag
"63bc2c6d-82d0"
content-type
font/woff
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
accept-ranges
bytes
content-length
33488
x-cdn-c
all
x-sg-cdn
1
memvYaGs126MiZpBA-UvWbX2vVnXBbObj2OVTS-muw.woff2
fonts.gstatic.com/s/opensans/v40/
47 KB
47 KB
Font
General
Full URL
https://fonts.gstatic.com/s/opensans/v40/memvYaGs126MiZpBA-UvWbX2vVnXBbObj2OVTS-muw.woff2
Requested by
Host: fonts.googleapis.com
URL: https://fonts.googleapis.com/css?family=Open+Sans%3A400%2C600%2C700%7CRoboto%3A400%2C500%2C700&display=swap&ver=12.2
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2404:6800:4004:80f::2003 , Australia, ASN15169 (GOOGLE, US),
Reverse DNS
Software
sffe /
Resource Hash
3c4d6a1421c7ddb7e404521fe8c4cd5be5af446d7689cd880be26612eaad3cfa
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://fonts.googleapis.com/
Origin
https://www.oncozine.com
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Thu, 04 Apr 2024 17:37:17 GMT
x-content-type-options
nosniff
age
318610
content-security-policy-report-only
require-trusted-types-for 'script'; report-uri https://csp.withgoogle.com/csp/apps-themes
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
48236
x-xss-protection
0
last-modified
Thu, 14 Dec 2023 02:08:40 GMT
server
sffe
cross-origin-opener-policy
same-origin; report-to="apps-themes"
report-to
{"group":"apps-themes","max_age":2592000,"endpoints":[{"url":"https://csp.withgoogle.com/csp/report-to/apps-themes"}]}
content-type
font/woff2
access-control-allow-origin
*
cache-control
public, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
expires
Fri, 04 Apr 2025 17:37:17 GMT
KFOlCnqEu92Fr1MmEU9fBBc4.woff2
fonts.gstatic.com/s/roboto/v30/
16 KB
16 KB
Font
General
Full URL
https://fonts.gstatic.com/s/roboto/v30/KFOlCnqEu92Fr1MmEU9fBBc4.woff2
Requested by
Host: fonts.googleapis.com
URL: https://fonts.googleapis.com/css?family=Open+Sans%3A400%2C600%2C700%7CRoboto%3A400%2C500%2C700&display=swap&ver=12.2
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2404:6800:4004:80f::2003 , Australia, ASN15169 (GOOGLE, US),
Reverse DNS
Software
sffe /
Resource Hash
b019538234514166ec7665359d097403358f8a4c991901983922fb4d56989f1e
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://fonts.googleapis.com/
Origin
https://www.oncozine.com
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Sat, 06 Apr 2024 21:49:04 GMT
x-content-type-options
nosniff
age
130703
content-security-policy-report-only
require-trusted-types-for 'script'; report-uri https://csp.withgoogle.com/csp/apps-themes
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
15920
x-xss-protection
0
last-modified
Wed, 11 May 2022 19:24:45 GMT
server
sffe
cross-origin-opener-policy
same-origin; report-to="apps-themes"
report-to
{"group":"apps-themes","max_age":2592000,"endpoints":[{"url":"https://csp.withgoogle.com/csp/report-to/apps-themes"}]}
content-type
font/woff2
access-control-allow-origin
*
cache-control
public, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
expires
Sun, 06 Apr 2025 21:49:04 GMT
KFOmCnqEu92Fr1Mu4mxK.woff2
fonts.gstatic.com/s/roboto/v30/
15 KB
16 KB
Font
General
Full URL
https://fonts.gstatic.com/s/roboto/v30/KFOmCnqEu92Fr1Mu4mxK.woff2
Requested by
Host: fonts.googleapis.com
URL: https://fonts.googleapis.com/css?family=Open+Sans%3A400%2C600%2C700%7CRoboto%3A400%2C500%2C700&display=swap&ver=12.2
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2404:6800:4004:80f::2003 , Australia, ASN15169 (GOOGLE, US),
Reverse DNS
Software
sffe /
Resource Hash
f6734f8177112c0839b961f96d813fcb189d81b60e96c33278c1983b6f419615
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://fonts.googleapis.com/
Origin
https://www.oncozine.com
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Tue, 02 Apr 2024 19:50:18 GMT
x-content-type-options
nosniff
age
483429
content-security-policy-report-only
require-trusted-types-for 'script'; report-uri https://csp.withgoogle.com/csp/apps-themes
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
15744
x-xss-protection
0
last-modified
Wed, 11 May 2022 19:24:48 GMT
server
sffe
cross-origin-opener-policy
same-origin; report-to="apps-themes"
report-to
{"group":"apps-themes","max_age":2592000,"endpoints":[{"url":"https://csp.withgoogle.com/csp/report-to/apps-themes"}]}
content-type
font/woff2
access-control-allow-origin
*
cache-control
public, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
expires
Wed, 02 Apr 2025 19:50:18 GMT
KFOlCnqEu92Fr1MmWUlfBBc4.woff2
fonts.gstatic.com/s/roboto/v30/
15 KB
16 KB
Font
General
Full URL
https://fonts.gstatic.com/s/roboto/v30/KFOlCnqEu92Fr1MmWUlfBBc4.woff2
Requested by
Host: fonts.googleapis.com
URL: https://fonts.googleapis.com/css?family=Open+Sans%3A400%2C600%2C700%7CRoboto%3A400%2C500%2C700&display=swap&ver=12.2
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2404:6800:4004:80f::2003 , Australia, ASN15169 (GOOGLE, US),
Reverse DNS
Software
sffe /
Resource Hash
f5aebdfea35d1e7656ef4acc5db1f243209755ae3300943ef8fc6280f363c860
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://fonts.googleapis.com/
Origin
https://www.oncozine.com
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Thu, 04 Apr 2024 02:44:37 GMT
x-content-type-options
nosniff
age
372170
content-security-policy-report-only
require-trusted-types-for 'script'; report-uri https://csp.withgoogle.com/csp/apps-themes
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
15860
x-xss-protection
0
last-modified
Wed, 11 May 2022 19:24:42 GMT
server
sffe
cross-origin-opener-policy
same-origin; report-to="apps-themes"
report-to
{"group":"apps-themes","max_age":2592000,"endpoints":[{"url":"https://csp.withgoogle.com/csp/report-to/apps-themes"}]}
content-type
font/woff2
access-control-allow-origin
*
cache-control
public, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
expires
Fri, 04 Apr 2025 02:44:37 GMT
izooto.js
cdn.izooto.com/scripts/sdk/
331 KB
78 KB
Script
General
Full URL
https://cdn.izooto.com/scripts/sdk/izooto.js
Requested by
Host: cdn.izooto.com
URL: https://cdn.izooto.com/scripts/31f2e0ece29b1c721db3d27d9d0230c2b049abcf.js?ver=3.7.16
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700::6812:d841 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
208306a5df3fda6e6fe5a6e56289208183f2b375c2017ea30196755a4cbafbe4
Security Headers
Name Value
X-Xss-Protection 1; mode=block

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:27 GMT
content-encoding
br
cf-cache-status
HIT
cf-bgj
minify
last-modified
Mon, 08 Apr 2024 07:59:28 GMT
server
cloudflare
age
7622
etag
W/"6613a3e0-52c0a"
vary
Accept-Encoding
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=1382400
cf-ray
87117355ace6af87-NRT
x-xss-protection
1; mode=block
expires
Wed, 24 Apr 2024 10:07:27 GMT
selectors
www.trendmd.com/journals/61664/ Frame
0
0
Preflight
General
Full URL
https://www.trendmd.com/journals/61664/selectors
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
172.67.159.150 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash

Request headers

Accept
*/*
Access-Control-Request-Headers
trendmd-widget-version
Access-Control-Request-Method
GET
Origin
https://www.oncozine.com
Sec-Fetch-Mode
cors
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36

Response headers

access-control-allow-credentials
true
access-control-allow-headers
trendmd-widget-version
access-control-allow-methods
GET, OPTIONS
access-control-allow-origin
https://www.oncozine.com
access-control-expose-headers
Trendmd-Article
access-control-max-age
1728000
alt-svc
h3=":443"; ma=86400
cache-control
no-transform
cf-cache-status
DYNAMIC
cf-ray
8711735628db6869-NRT
content-length
7
content-type
text/plain; charset=utf-8
date
Mon, 08 Apr 2024 10:07:27 GMT
nel
{"success_fraction":0,"report_to":"cf-nel","max_age":604800}
report-to
{"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=uOTEMHRGLLLdjbfVGyuDmOYzXIyP4vAVp3cLgZl1H3RDGHrKt7CT4a6Son0F5P2oy4B%2F5s7Djhy%2FV23UypGxLKTGHbwnph6AP32xqWLNeryLFOZhZXaDojqMozl%2Bz6o8IBw%3D"}],"group":"cf-nel","max_age":604800}
server
cloudflare
vary
origin
selectors
www.trendmd.com/journals/61664/
1 KB
2 KB
Fetch
General
Full URL
https://www.trendmd.com/journals/61664/selectors
Requested by
Host: js.trendmd.com
URL: https://js.trendmd.com/trendmd.min.js
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
172.67.159.150 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
49de713da806324d408d080b4f7df12c056fb4b50800a20f9a114ac02b239147
Security Headers
Name Value
X-Frame-Options SAMEORIGIN
X-Xss-Protection 1; mode=block

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
trendmd-widget-version
3.140.0
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:28 GMT
content-encoding
gzip
cf-cache-status
DYNAMIC
nel
{"success_fraction":0,"report_to":"cf-nel","max_age":604800}
alt-svc
h3=":443"; ma=86400
x-xss-protection
1; mode=block
server
cloudflare
x-frame-options
SAMEORIGIN
access-control-max-age
1728000
access-control-allow-methods
GET, OPTIONS
content-type
application/json; charset=utf-8
access-control-allow-origin
https://www.oncozine.com
cache-control
no-transform,no-store
access-control-allow-credentials
true
vary
origin,accept-encoding
report-to
{"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=hOa3UZnM6tAvyVPLycH84D7oeN7fPRMQCW9aos6TZglh3xTGh%2F31FQhsoPDBKJ9l6otwYAMkUx0qehrhQB3yOcEm6bZar93926XFQPDH1ncyeW5ePdx4NoHh%2FcGRPX%2FpDf0%3D"}],"group":"cf-nel","max_age":604800}
cf-ray
871173576b02f5e1-NRT
access-control-allow-headers
trendmd-widget-version
client.json
s3-us-west-2.amazonaws.com/mfesecure-public/host/oncozine.com/
170 B
1001 B
XHR
General
Full URL
https://s3-us-west-2.amazonaws.com/mfesecure-public/host/oncozine.com/client.json?source=jsmain
Requested by
Host: cdn.ywxi.net
URL: https://cdn.ywxi.net/js/1.js
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.92.148.72 Boardman, United States, ASN16509 (AMAZON-02, US),
Reverse DNS
s3-us-west-2.amazonaws.com
Software
AmazonS3 /
Resource Hash
9645050dc9d4f167d9e8376c90bf624d764299b52c82232b433770f6002fa09a

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

Date
Mon, 08 Apr 2024 10:07:29 GMT
Content-Encoding
gzip
x-amz-version-id
ozX9Hlr9bpa1nQJnkEpx5ai4naVNoSmU
x-amz-request-id
V48NEXAN5CXZ28J2
x-amz-server-side-encryption
AES256
x-amz-replication-status
COMPLETED
Content-Length
151
x-amz-id-2
Lu1lPdAXz9FM7zNyandCec5T4O0V56uNxIvd6gbbkJUz2AEtVGJ/tZdKeZjjQgx45rKUtGAcnF0=
Last-Modified
Thu, 04 Apr 2024 16:01:06 GMT
Server
AmazonS3
ETag
"d6fe2a88a4f591fa4e1889a1382c50bd"
Access-Control-Max-Age
60
Access-Control-Allow-Methods
GET, HEAD
Content-Type
application/json
Access-Control-Allow-Origin
https://www.oncozine.com
Access-Control-Expose-Headers
Access-Control-Allow-Origin
Vary
Origin, Access-Control-Request-Headers, Access-Control-Request-Method
Access-Control-Allow-Credentials
true
Cache-Control
public, max-age=60
Accept-Ranges
bytes
client.json
s3-us-west-2.amazonaws.com/mfesecure-public/host/oncozine.com/
170 B
1001 B
XHR
General
Full URL
https://s3-us-west-2.amazonaws.com/mfesecure-public/host/oncozine.com/client.json?source=jsinline
Requested by
Host: cdn.ywxi.net
URL: https://cdn.ywxi.net/js/1.js
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.92.148.72 Boardman, United States, ASN16509 (AMAZON-02, US),
Reverse DNS
s3-us-west-2.amazonaws.com
Software
AmazonS3 /
Resource Hash
9645050dc9d4f167d9e8376c90bf624d764299b52c82232b433770f6002fa09a

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

Date
Mon, 08 Apr 2024 10:07:29 GMT
Content-Encoding
gzip
x-amz-version-id
ozX9Hlr9bpa1nQJnkEpx5ai4naVNoSmU
x-amz-request-id
V48G3CR3N6ZZCR5P
x-amz-server-side-encryption
AES256
x-amz-replication-status
COMPLETED
Content-Length
151
x-amz-id-2
ysOjTk05BWvqy7+wZO0ydLzzbdt9jIW0OYwbGMvH8wHEvCQ1yGDjLx1rt63nSrKfPzlayfW2zeA=
Last-Modified
Thu, 04 Apr 2024 16:01:06 GMT
Server
AmazonS3
ETag
"d6fe2a88a4f591fa4e1889a1382c50bd"
Access-Control-Max-Age
60
Access-Control-Allow-Methods
GET, HEAD
Content-Type
application/json
Access-Control-Allow-Origin
https://www.oncozine.com
Access-Control-Expose-Headers
Access-Control-Allow-Origin
Vary
Origin, Access-Control-Request-Headers, Access-Control-Request-Method
Access-Control-Allow-Credentials
true
Cache-Control
public, max-age=60
Accept-Ranges
bytes
show_ads_impl_fy2021.js
pagead2.googlesyndication.com/pagead/managed/js/adsense/m202404020101/
406 KB
138 KB
Script
General
Full URL
https://pagead2.googlesyndication.com/pagead/managed/js/adsense/m202404020101/show_ads_impl_fy2021.js
Requested by
Host: pagead2.googlesyndication.com
URL: https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
216.58.220.130 , United States, ASN15169 (GOOGLE, US),
Reverse DNS
syd09s01-in-f130.1e100.net
Software
cafe /
Resource Hash
b9e718eaf1425b948a8e6439cfa609fe2c44ad5b494a097b1c1cc574c3f73d98
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:27 GMT
content-encoding
br
x-content-type-options
nosniff
p3p
policyref="https://www.googleadservices.com/pagead/p3p.xml", CP="NOI DEV PSA PSD IVA IVD OTP OUR OTR IND OTC"
cross-origin-resource-policy
cross-origin
content-disposition
attachment; filename="f.txt"
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
140999
x-xss-protection
0
server
cafe
etag
7686596581447760644
vary
Accept-Encoding
content-type
text/javascript; charset=UTF-8
cache-control
private, max-age=1209600
timing-allow-origin
*
expires
Mon, 08 Apr 2024 10:07:27 GMT
manage
router.infolinks.com/usync/ Frame 2758
0
0
Document
General
Full URL
https://router.infolinks.com/usync/manage?pid=3379170&wsid=0&pdom=www.oncozine.com&purl=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F
Requested by
Host: resources.infolinks.com
URL: https://resources.infolinks.com/js/1928.005-3.034/ice.js
Protocol
H2
Security
TLS 1.2, ECDHE_ECDSA, AES_128_GCM
Server
172.66.42.247 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash

Request headers

Referer
https://www.oncozine.com/
Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
accept-language
jp-JP,jp;q=0.9
sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
sec-ch-ua-mobile
?0
sec-ch-ua-platform
"Win32"

Response headers

cache-control
no-store
cf-cache-status
DYNAMIC
cf-ray
871173568db47349-NRT
content-encoding
gzip
content-type
text/html;charset=UTF-8
date
Mon, 08 Apr 2024 10:07:27 GMT
p3p
CP="NON DSP NID OUR COR"
server
cloudflare
via
1.1 google
lcmanage
router.infolinks.com/usync/
0
43 B
Script
General
Full URL
https://router.infolinks.com/usync/lcmanage?pid=3379170&wsid=0&pdom=www.oncozine.com&purl=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F
Requested by
Host: resources.infolinks.com
URL: https://resources.infolinks.com/js/1928.005-3.034/ice.js
Protocol
H2
Security
TLS 1.2, ECDHE_ECDSA, AES_128_GCM
Server
172.66.42.247 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:27 GMT
cache-control
no-store
via
1.1 google
cf-cache-status
DYNAMIC
server
cloudflare
cf-ray
87117356782e6848-NRT
content-length
0
gsd
router.infolinks.com/
323 B
524 B
Script
General
Full URL
https://router.infolinks.com/gsd?evt=afterGSD&pid=3379170&pdom=www.oncozine.com&purl=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&jsv=1928.005-3.034&_cb=17125708477580
Requested by
Host: resources.infolinks.com
URL: https://resources.infolinks.com/js/1928.005-3.034/ice.js
Protocol
H2
Security
TLS 1.2, ECDHE_ECDSA, AES_128_GCM
Server
172.66.42.247 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
1ce09f43a9fd65845654c6c484438aeceb554fc00866e3f378c7dbb283f7682f

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

pragma
no-cache
date
Mon, 08 Apr 2024 10:07:27 GMT
via
1.1 google
content-encoding
gzip
cf-cache-status
DYNAMIC
server
cloudflare
content-type
text/javascript;charset=UTF-8
p3p
CP="NON DSP NID OUR COR"
cache-control
max-age=0
cf-ray
87117356782a6848-NRT
expires
Thu, 01 Jan 1970 00:00:00 GMT
js
www.googletagmanager.com/gtag/
244 KB
86 KB
Script
General
Full URL
https://www.googletagmanager.com/gtag/js?id=G-MW8SS19QHB&l=dataLayer&cx=c
Requested by
Host: www.googletagmanager.com
URL: https://www.googletagmanager.com/gtag/js?id=UA-188673758-1&l=dataLayer&cx=c
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
172.217.175.72 , United States, ASN15169 (GOOGLE, US),
Reverse DNS
nrt20s20-in-f8.1e100.net
Software
Google Tag Manager /
Resource Hash
1633feb01fd29b1b0000748fabf1ad1818487ea96229290d573c9b4f6c1235f5
Security Headers
Name Value
Strict-Transport-Security max-age=31536000; includeSubDomains
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:27 GMT
content-encoding
br
strict-transport-security
max-age=31536000; includeSubDomains
server
Google Tag Manager
vary
Accept-Encoding
content-type
application/javascript; charset=UTF-8
access-control-allow-origin
*
cache-control
private, max-age=900
access-control-allow-credentials
true
cross-origin-resource-policy
cross-origin
access-control-allow-headers
Cache-Control
content-length
88427
x-xss-protection
0
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
expires
Mon, 08 Apr 2024 10:07:27 GMT
analytics.js
www.google-analytics.com/
52 KB
21 KB
Script
General
Full URL
https://www.google-analytics.com/analytics.js
Requested by
Host: www.googletagmanager.com
URL: https://www.googletagmanager.com/gtag/js?id=UA-188673758-1&l=dataLayer&cx=c
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2404:6800:4004:80b::200e , Australia, ASN15169 (GOOGLE, US),
Reverse DNS
Software
Golfe2 /
Resource Hash
de36e50194320a7d3ef1ace9bd34a875a8bd458b253c061979dd628e9bf49afd
Security Headers
Name Value
Strict-Transport-Security max-age=10886400; includeSubDomains; preload
X-Content-Type-Options nosniff

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

strict-transport-security
max-age=10886400; includeSubDomains; preload
content-encoding
gzip
x-content-type-options
nosniff
date
Mon, 08 Apr 2024 08:42:45 GMT
last-modified
Tue, 12 Dec 2023 18:09:08 GMT
server
Golfe2
age
5082
vary
Accept-Encoding
content-type
text/javascript
cache-control
public, max-age=7200
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
20994
expires
Mon, 08 Apr 2024 10:42:45 GMT
collect
www.google-analytics.com/g/
0
45 B
Ping
General
Full URL
https://www.google-analytics.com/g/collect?v=2&tid=G-PGDBN4WRNY&gtm=45je4430v876608970za200&_p=1712570846381&gcd=13l3l3l3l1&npa=0&dma=0&gdid=dZGIzZG&cid=227320689.1712570847&ul=en-us&sr=800x600&uaa=x86&uab=64&uafvl=Google%2520Chrome%3B123.0.6312.105%7CNot%253AA-Brand%3B8.0.0.0%7CChromium%3B123.0.6312.105&uamb=0&uam=&uap=Win32&uapv=10.0.0&uaw=0&pscdl=noapi&_eu=AAAC&_s=2&sid=1712570846&sct=1&seg=1&dl=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&dt=U.S.%20FDA%20approves%20Phase%203%20Study%20Design%20for%20Zilovertamab%20in%20the%20Treatment%20of%20Mantle%20Cell%20Lymphoma%20-%20Onco%27Zine&en=page_view&_ee=1&_et=2&tfd=1803
Requested by
Host: www.googletagmanager.com
URL: https://www.googletagmanager.com/gtag/js?id=G-PGDBN4WRNY
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2404:6800:4004:80b::200e , Australia, ASN15169 (GOOGLE, US),
Reverse DNS
Software
Golfe2 /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

pragma
no-cache
date
Mon, 08 Apr 2024 10:07:27 GMT
server
Golfe2
content-type
text/plain
access-control-allow-origin
https://www.oncozine.com
cache-control
no-cache, no-store, must-revalidate
access-control-allow-credentials
true
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
0
expires
Fri, 01 Jan 1990 00:00:00 GMT
iz_setcid.html
cdn.izooto.com/scripts/sak/ Frame 3DFD
0
0
Document
General
Full URL
https://cdn.izooto.com/scripts/sak/iz_setcid.html?v=1
Requested by
Host: cdn.izooto.com
URL: https://cdn.izooto.com/scripts/sdk/izooto.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700::6812:d941 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
Security Headers
Name Value
X-Xss-Protection 1; mode=block

Request headers

Referer
https://www.oncozine.com/
Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
accept-language
jp-JP,jp;q=0.9
sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
sec-ch-ua-mobile
?0
sec-ch-ua-platform
"Win32"

Response headers

access-control-allow-origin
*
age
141050
cache-control
public, max-age=2678400
cf-cache-status
HIT
cf-ray
871173571b74af60-NRT
content-encoding
br
content-type
text/html
date
Mon, 08 Apr 2024 10:07:27 GMT
expires
Thu, 09 May 2024 10:07:27 GMT
last-modified
Tue, 07 Feb 2023 10:27:13 GMT
server
cloudflare
vary
Accept-Encoding
x-xss-protection
1; mode=block
collect
www.google-analytics.com/j/
1 B
21 B
XHR
General
Full URL
https://www.google-analytics.com/j/collect?v=1&_v=j101&a=601469149&t=pageview&_s=1&dl=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&ul=en-us&de=UTF-8&dt=U.S.%20FDA%20approves%20Phase%203%20Study%20Design%20for%20Zilovertamab%20in%20the%20Treatment%20of%20Mantle%20Cell%20Lymphoma%20-%20Onco%27Zine&sd=24-bit&sr=800x600&vp=1600x1113&je=0&_u=YADAAUABAAAAACAAI~&jid=1178276595&gjid=460690941&cid=227320689.1712570847&tid=UA-188673758-1&_gid=341405600.1712570848&_r=1&gtm=457e4430z8876608970za200&gcd=13l3l3l3l1&dma=0&jsscut=1&z=905016908
Requested by
Host: www.google-analytics.com
URL: https://www.google-analytics.com/analytics.js
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
142.250.196.142 , United States, ASN15169 (GOOGLE, US),
Reverse DNS
nrt12s36-in-f14.1e100.net
Software
Golfe2 /
Resource Hash
6b86b273ff34fce19d6b804eff5a3f5747ada4eaa22f1d49c01e52ddb7875b4b
Security Headers
Name Value
X-Content-Type-Options nosniff

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
sec-ch-ua-platform
"Win32"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
Content-Type
text/plain

Response headers

pragma
no-cache
date
Mon, 08 Apr 2024 10:07:27 GMT
x-content-type-options
nosniff
last-modified
Sun, 17 May 1998 03:00:00 GMT
server
Golfe2
content-type
text/plain
access-control-allow-origin
https://www.oncozine.com
cache-control
no-cache, no-store, must-revalidate
access-control-allow-credentials
true
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
1
expires
Fri, 01 Jan 1990 00:00:00 GMT
collect
www.google-analytics.com/j/
15 B
35 B
XHR
General
Full URL
https://www.google-analytics.com/j/collect?v=1&_v=j101&a=601469149&t=pageview&_s=1&dl=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&ul=en-us&de=UTF-8&dt=U.S.%20FDA%20approves%20Phase%203%20Study%20Design%20for%20Zilovertamab%20in%20the%20Treatment%20of%20Mantle%20Cell%20Lymphoma%20-%20Onco%27Zine&sd=24-bit&sr=800x600&vp=1600x1113&je=0&_u=YADAAUABAAAAACAAI~&jid=699183903&gjid=334363748&cid=227320689.1712570847&tid=UA-188673758-1&_gid=341405600.1712570848&_r=1&_slc=1&gtm=45He4430n81T5CT8SPv839587796za200&gcd=13l3l3l3l1&dma=0&z=1359614311
Requested by
Host: www.google-analytics.com
URL: https://www.google-analytics.com/analytics.js
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
142.250.196.142 , United States, ASN15169 (GOOGLE, US),
Reverse DNS
nrt12s36-in-f14.1e100.net
Software
Golfe2 /
Resource Hash
4004d8d2f32a50315c1c8c7a1c51d94e7c627c1fbeb190229fe42a35156d538d
Security Headers
Name Value
X-Content-Type-Options nosniff

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
sec-ch-ua-platform
"Win32"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
Content-Type
text/plain

Response headers

pragma
no-cache
date
Mon, 08 Apr 2024 10:07:27 GMT
x-content-type-options
nosniff
last-modified
Sun, 17 May 1998 03:00:00 GMT
server
Golfe2
content-type
text/plain
access-control-allow-origin
https://www.oncozine.com
cache-control
no-cache, no-store, must-revalidate
access-control-allow-credentials
true
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
15
expires
Fri, 01 Jan 1990 00:00:00 GMT
collect
www.google-analytics.com/
35 B
55 B
Image
General
Full URL
https://www.google-analytics.com/collect?v=1&_v=j101&a=601469149&t=event&ni=1&_s=1&dl=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&ul=en-us&de=UTF-8&dt=U.S.%20FDA%20approves%20Phase%203%20Study%20Design%20for%20Zilovertamab%20in%20the%20Treatment%20of%20Mantle%20Cell%20Lymphoma%20-%20Onco%27Zine&sd=24-bit&sr=800x600&vp=1600x1113&je=0&ec=Adverts&ea=Impression&el=St%20Jude%20728x90%20footer&ev=2&_u=YADAAUABAAAAACAAI~&jid=&gjid=&cid=227320689.1712570847&tid=UA-188673758-1&_gid=341405600.1712570848&gtm=45He4430n81T5CT8SPv839587796za200&gcd=13l3l3l3l1&dma=0&z=456162832
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
142.250.196.142 , United States, ASN15169 (GOOGLE, US),
Reverse DNS
nrt12s36-in-f14.1e100.net
Software
Golfe2 /
Resource Hash
8337212354871836e6763a41e615916c89bac5b3f1f0adf60ba43c7c806e1015
Security Headers
Name Value
X-Content-Type-Options nosniff

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

pragma
no-cache
date
Sun, 07 Apr 2024 15:25:15 GMT
x-content-type-options
nosniff
last-modified
Sun, 17 May 1998 03:00:00 GMT
server
Golfe2
age
67332
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
35
expires
Mon, 01 Jan 1990 00:00:00 GMT
collect
www.google-analytics.com/
35 B
55 B
Image
General
Full URL
https://www.google-analytics.com/collect?v=1&_v=j101&a=601469149&t=event&ni=1&_s=1&dl=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&ul=en-us&de=UTF-8&dt=U.S.%20FDA%20approves%20Phase%203%20Study%20Design%20for%20Zilovertamab%20in%20the%20Treatment%20of%20Mantle%20Cell%20Lymphoma%20-%20Onco%27Zine&sd=24-bit&sr=800x600&vp=1600x1113&je=0&ec=Adverts&ea=Impression&el=St%20Jude%20728x90%20footer&ev=2&_u=YADAAUABAAAAACAAI~&jid=&gjid=&cid=227320689.1712570847&tid=UA-188673758-1&_gid=341405600.1712570848&gtm=45He4430n81T5CT8SPv839587796za200&gcd=13l3l3l3l1&dma=0&z=1785363698
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
142.250.196.142 , United States, ASN15169 (GOOGLE, US),
Reverse DNS
nrt12s36-in-f14.1e100.net
Software
Golfe2 /
Resource Hash
8337212354871836e6763a41e615916c89bac5b3f1f0adf60ba43c7c806e1015
Security Headers
Name Value
X-Content-Type-Options nosniff

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

pragma
no-cache
date
Sun, 07 Apr 2024 15:25:15 GMT
x-content-type-options
nosniff
last-modified
Sun, 17 May 1998 03:00:00 GMT
server
Golfe2
age
67332
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
35
expires
Mon, 01 Jan 1990 00:00:00 GMT
collect
www.google-analytics.com/
35 B
55 B
Image
General
Full URL
https://www.google-analytics.com/collect?v=1&_v=j101&a=601469149&t=event&ni=1&_s=1&dl=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&ul=en-us&de=UTF-8&dt=U.S.%20FDA%20approves%20Phase%203%20Study%20Design%20for%20Zilovertamab%20in%20the%20Treatment%20of%20Mantle%20Cell%20Lymphoma%20-%20Onco%27Zine&sd=24-bit&sr=800x600&vp=1600x1113&je=0&ec=Adverts&ea=Impression&el=St%20Jude%20728x90%20footer&ev=2&_u=YADAAUABAAAAACAAI~&jid=&gjid=&cid=227320689.1712570847&tid=UA-188673758-1&_gid=341405600.1712570848&gtm=45He4430n81T5CT8SPv839587796za200&gcd=13l3l3l3l1&dma=0&z=724909255
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
142.250.196.142 , United States, ASN15169 (GOOGLE, US),
Reverse DNS
nrt12s36-in-f14.1e100.net
Software
Golfe2 /
Resource Hash
8337212354871836e6763a41e615916c89bac5b3f1f0adf60ba43c7c806e1015
Security Headers
Name Value
X-Content-Type-Options nosniff

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

pragma
no-cache
date
Sun, 07 Apr 2024 15:25:15 GMT
x-content-type-options
nosniff
last-modified
Sun, 17 May 1998 03:00:00 GMT
server
Golfe2
age
67332
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
35
expires
Mon, 01 Jan 1990 00:00:00 GMT
collect
www.google-analytics.com/
35 B
55 B
Image
General
Full URL
https://www.google-analytics.com/collect?v=1&_v=j101&a=601469149&t=event&ni=1&_s=1&dl=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&ul=en-us&de=UTF-8&dt=U.S.%20FDA%20approves%20Phase%203%20Study%20Design%20for%20Zilovertamab%20in%20the%20Treatment%20of%20Mantle%20Cell%20Lymphoma%20-%20Onco%27Zine&sd=24-bit&sr=800x600&vp=1600x1113&je=0&ec=Adverts&ea=Impression&el=St%20Jude%20728x90%20footer&ev=2&_u=YADAAUABAAAAACAAI~&jid=&gjid=&cid=227320689.1712570847&tid=UA-188673758-1&_gid=341405600.1712570848&gtm=45He4430n81T5CT8SPv839587796za200&gcd=13l3l3l3l1&dma=0&z=1816902701
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
142.250.196.142 , United States, ASN15169 (GOOGLE, US),
Reverse DNS
nrt12s36-in-f14.1e100.net
Software
Golfe2 /
Resource Hash
8337212354871836e6763a41e615916c89bac5b3f1f0adf60ba43c7c806e1015
Security Headers
Name Value
X-Content-Type-Options nosniff

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

pragma
no-cache
date
Sun, 07 Apr 2024 15:25:15 GMT
x-content-type-options
nosniff
last-modified
Sun, 17 May 1998 03:00:00 GMT
server
Golfe2
age
67332
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
35
expires
Mon, 01 Jan 1990 00:00:00 GMT
collect
www.google-analytics.com/
35 B
55 B
Image
General
Full URL
https://www.google-analytics.com/collect?v=1&_v=j101&a=601469149&t=event&ni=1&_s=1&dl=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&ul=en-us&de=UTF-8&dt=U.S.%20FDA%20approves%20Phase%203%20Study%20Design%20for%20Zilovertamab%20in%20the%20Treatment%20of%20Mantle%20Cell%20Lymphoma%20-%20Onco%27Zine&sd=24-bit&sr=800x600&vp=1600x1113&je=0&ec=Adverts&ea=Impression&el=St%20Jude%20728x90%20footer&ev=2&_u=YADAAUABAAAAACAAI~&jid=&gjid=&cid=227320689.1712570847&tid=UA-188673758-1&_gid=341405600.1712570848&gtm=45He4430n81T5CT8SPv839587796za200&gcd=13l3l3l3l1&dma=0&z=1135666680
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
142.250.196.142 , United States, ASN15169 (GOOGLE, US),
Reverse DNS
nrt12s36-in-f14.1e100.net
Software
Golfe2 /
Resource Hash
8337212354871836e6763a41e615916c89bac5b3f1f0adf60ba43c7c806e1015
Security Headers
Name Value
X-Content-Type-Options nosniff

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

pragma
no-cache
date
Sun, 07 Apr 2024 15:25:15 GMT
x-content-type-options
nosniff
last-modified
Sun, 17 May 1998 03:00:00 GMT
server
Golfe2
age
67332
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
35
expires
Mon, 01 Jan 1990 00:00:00 GMT
js
www.googletagmanager.com/gtag/
248 KB
88 KB
Script
General
Full URL
https://www.googletagmanager.com/gtag/js?id=G-MW8SS19QHB&cx=c&_slc=1
Requested by
Host: www.google-analytics.com
URL: https://www.google-analytics.com/analytics.js
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
172.217.175.72 , United States, ASN15169 (GOOGLE, US),
Reverse DNS
nrt20s20-in-f8.1e100.net
Software
Google Tag Manager /
Resource Hash
cb958173209439c3ddd7e0f62c147d0c511158e0a6a5449310f273d6535c10c1
Security Headers
Name Value
Strict-Transport-Security max-age=31536000; includeSubDomains
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:27 GMT
content-encoding
br
strict-transport-security
max-age=31536000; includeSubDomains
server
Google Tag Manager
vary
Accept-Encoding
content-type
application/javascript; charset=UTF-8
access-control-allow-origin
*
cache-control
private, max-age=900
access-control-allow-credentials
true
cross-origin-resource-policy
cross-origin
access-control-allow-headers
Cache-Control
content-length
90186
x-xss-protection
0
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
expires
Mon, 08 Apr 2024 10:07:27 GMT
doq.htm
rt3073.infolinks.com/action/
1 KB
1 KB
XHR
General
Full URL
https://rt3073.infolinks.com/action/doq.htm?pcode=utf-8&r=17125708479211
Requested by
Host: resources.infolinks.com
URL: https://resources.infolinks.com/js/1928.005-3.034/ice.js
Protocol
H2
Security
TLS 1.2, ECDHE_ECDSA, AES_128_GCM
Server
172.66.41.9 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
44fd31c1a78d60ab373c9b60561b93a0afdb7fd0005117ee2e6154ca5aa2bf3c

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
sec-ch-ua-platform
"Win32"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
Content-type
application/x-www-form-urlencoded

Response headers

pragma
no-cache
date
Mon, 08 Apr 2024 10:07:28 GMT
content-encoding
gzip
cf-cache-status
DYNAMIC
server
cloudflare
vary
Origin, Access-Control-Request-Method, Access-Control-Request-Headers
p3p
CP="NON DSP NID OUR COR"
access-control-allow-origin
https://www.oncozine.com
content-type
text/html;charset=UTF-8
cache-control
no-cache,no-store
content-language
jp-JP
cf-ray
871173579f09af28-NRT
expires
Thu, 01 Jan 1970 00:00:00 GMT
rum_fy2021.js
pagead2.googlesyndication.com/pagead/js/r20240403/r20110914/
56 KB
22 KB
Script
General
Full URL
https://pagead2.googlesyndication.com/pagead/js/r20240403/r20110914/rum_fy2021.js
Requested by
Host: pagead2.googlesyndication.com
URL: https://pagead2.googlesyndication.com/pagead/managed/js/adsense/m202404020101/show_ads_impl_fy2021.js
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
216.58.220.130 , United States, ASN15169 (GOOGLE, US),
Reverse DNS
syd09s01-in-f130.1e100.net
Software
cafe /
Resource Hash
77cbbb2d775cd5edb60ca5e0a8b6c8713666fc7440fecb731a6ddc628edc8861
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Sun, 07 Apr 2024 21:36:56 GMT
content-encoding
br
x-content-type-options
nosniff
age
45031
p3p
policyref="https://www.googleadservices.com/pagead/p3p.xml", CP="NOI DEV PSA PSD IVA IVD OTP OUR OTR IND OTC"
cross-origin-resource-policy
cross-origin
content-disposition
attachment; filename="f.txt"
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
22102
x-xss-protection
0
server
cafe
etag
17254745959749703337
vary
Accept-Encoding
content-type
text/javascript; charset=UTF-8
cache-control
public, max-age=1209600
timing-allow-origin
*
expires
Sun, 21 Apr 2024 21:36:56 GMT
ads
googleads.g.doubleclick.net/pagead/ Frame 4119
0
0
Document
General
Full URL
https://googleads.g.doubleclick.net/pagead/ads?client=ca-pub-8204247984439341&output=html&adk=1812271804&adf=3025194257&lmt=1712570847&plat=1%3A16777216%2C2%3A16777216%2C3%3A16%2C4%3A16%2C9%3A32776%2C16%3A8388608%2C17%3A32%2C24%3A32%2C25%3A32%2C30%3A1081344%2C32%3A32%2C41%3A32%2C42%3A32&format=0x0&url=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&pra=5&wgl=1&easpi=0&asro=0&uach=WyJXaW4zMiIsIjEwLjAuMCIsIng4NiIsIiIsIjEyMy4wLjYzMTIuMTA1IixudWxsLDAsbnVsbCwiNjQiLFtbIkdvb2dsZSBDaHJvbWUiLCIxMjMuMC42MzEyLjEwNSJdLFsiTm90OkEtQnJhbmQiLCI4LjAuMC4wIl0sWyJDaHJvbWl1bSIsIjEyMy4wLjYzMTIuMTA1Il1dLDBd&dt=1712570847721&bpp=2&bdt=1457&idt=209&shv=r20240403&mjsv=m202404020101&ptt=9&saldr=aa&abxe=1&nras=1&correlator=5137455438121&rume=1&frm=20&pv=2&ga_vid=227320689.1712570847&ga_sid=1712570848&ga_hid=601469149&ga_fc=1&u_tz=540&u_his=2&u_h=600&u_w=800&u_ah=600&u_aw=800&u_cd=24&u_sd=1&dmc=8&adx=-12245933&ady=-12245933&biw=1600&bih=1113&scr_x=0&scr_y=0&eid=44759875%2C44759926%2C44759837%2C95329025%2C95329439%2C95329462%2C95329571%2C31081717%2C31061691%2C31061692&oid=2&pvsid=4282168737799688&tmod=702938097&uas=0&nvt=1&fsapi=1&fc=1920&brdim=170%2C170%2C170%2C170%2C800%2C0%2C1600%2C1200%2C1600%2C1113&vis=1&rsz=%7C%7Cs%7C&abl=NS&fu=32768&bc=31&bz=1&psd=W251bGwsbnVsbCxudWxsLDNd&ifi=1&uci=a!1&fsb=1&dtd=230
Requested by
Host: pagead2.googlesyndication.com
URL: https://pagead2.googlesyndication.com/pagead/managed/js/adsense/m202404020101/show_ads_impl_fy2021.js
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
142.251.42.194 Queens, United States, ASN15169 (GOOGLE, US),
Reverse DNS
nrt12s47-in-f2.1e100.net
Software
cafe /
Resource Hash
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Referer
https://www.oncozine.com/
Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
accept-language
jp-JP,jp;q=0.9
sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
sec-ch-ua-mobile
?0
sec-ch-ua-platform
"Win32"

Response headers

alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
cache-control
private
content-encoding
br
content-length
46
content-type
text/html; charset=UTF-8
cross-origin-resource-policy
cross-origin
date
Mon, 08 Apr 2024 10:07:28 GMT
expires
Mon, 08 Apr 2024 10:07:28 GMT
p3p
policyref="https://googleads.g.doubleclick.net/pagead/gcn_p3p_.xml", CP="CURa ADMa DEVa TAIo PSAo PSDo OUR IND UNI PUR INT DEM STA PRE COM NAV OTC NOI DSP COR"
server
cafe
timing-allow-origin
*
x-content-type-options
nosniff
x-xss-protection
0
gen_204
pagead2.googlesyndication.com/pagead/
0
20 B
Image
General
Full URL
https://pagead2.googlesyndication.com/pagead/gen_204?id=ach_evt&tn=DIV&id=subscription-popup&ign=false&pw=1600&ph=1113&x=0&y=973.8
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
216.58.220.130 , United States, ASN15169 (GOOGLE, US),
Reverse DNS
syd09s01-in-f130.1e100.net
Software
cafe /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

pragma
no-cache
date
Mon, 08 Apr 2024 10:07:27 GMT
x-content-type-options
nosniff
server
cafe
content-type
image/gif
p3p
policyref="https://www.googleadservices.com/pagead/p3p.xml", CP="NOI DEV PSA PSD IVA IVD OTP OUR OTR IND OTC"
cache-control
no-cache, must-revalidate
cross-origin-resource-policy
cross-origin
timing-allow-origin
*
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
0
x-xss-protection
0
expires
Fri, 01 Jan 1990 00:00:00 GMT
gen_204
pagead2.googlesyndication.com/pagead/
0
20 B
Image
General
Full URL
https://pagead2.googlesyndication.com/pagead/gen_204?id=ach_evt&tn=DIV&id=subscription-popup&ign=false&pw=1600&ph=1113&x=0&y=0
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
216.58.220.130 , United States, ASN15169 (GOOGLE, US),
Reverse DNS
syd09s01-in-f130.1e100.net
Software
cafe /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

pragma
no-cache
date
Mon, 08 Apr 2024 10:07:27 GMT
x-content-type-options
nosniff
server
cafe
content-type
image/gif
p3p
policyref="https://www.googleadservices.com/pagead/p3p.xml", CP="NOI DEV PSA PSD IVA IVD OTP OUR OTR IND OTC"
cache-control
no-cache, must-revalidate
cross-origin-resource-policy
cross-origin
timing-allow-origin
*
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
0
x-xss-protection
0
expires
Fri, 01 Jan 1990 00:00:00 GMT
collect
www.google-analytics.com/g/
0
17 B
Ping
General
Full URL
https://www.google-analytics.com/g/collect?v=2&tid=G-MW8SS19QHB&gtm=45je4430v9165113704za200&_p=1712570846381&gcd=13l3l3l3l1&npa=0&dma=0&cid=227320689.1712570847&ul=en-us&sr=800x600&ir=1&uaa=x86&uab=64&uafvl=Google%2520Chrome%3B123.0.6312.105%7CNot%253AA-Brand%3B8.0.0.0%7CChromium%3B123.0.6312.105&uamb=0&uam=&uap=Win32&uapv=10.0.0&uaw=0&pscdl=noapi&_eu=EAAI&_s=1&sid=1712570847&sct=1&seg=0&dl=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&dt=U.S.%20FDA%20approves%20Phase%203%20Study%20Design%20for%20Zilovertamab%20in%20the%20Treatment%20of%20Mantle%20Cell%20Lymphoma%20-%20Onco%27Zine&en=page_view&_fv=1&_ss=1&tfd=1951
Requested by
Host: www.googletagmanager.com
URL: https://www.googletagmanager.com/gtag/js?id=G-MW8SS19QHB&l=dataLayer&cx=c
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
142.250.196.142 , United States, ASN15169 (GOOGLE, US),
Reverse DNS
nrt12s36-in-f14.1e100.net
Software
Golfe2 /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

pragma
no-cache
date
Mon, 08 Apr 2024 10:07:28 GMT
server
Golfe2
content-type
text/plain
access-control-allow-origin
https://www.oncozine.com
cache-control
no-cache, no-store, must-revalidate
access-control-allow-credentials
true
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
0
expires
Fri, 01 Jan 1990 00:00:00 GMT
in_search.js
resources.infolinks.com/js/1928.005-3.034/
234 KB
92 KB
Script
General
Full URL
https://resources.infolinks.com/js/1928.005-3.034/in_search.js
Requested by
Host: resources.infolinks.com
URL: https://resources.infolinks.com/js/1928.005-3.034/ice.js
Protocol
H2
Security
TLS 1.2, ECDHE_ECDSA, AES_128_GCM
Server
172.66.42.247 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
9b46bc1cdac4ab275468dbc876d0db1df58cb4c8e017b6c9bf30fc935e87a846

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:28 GMT
via
1.1 google
content-encoding
gzip
cf-cache-status
HIT
last-modified
Tue, 02 Apr 2024 06:51:09 GMT
server
cloudflare
age
8738
etag
W/"3a86d-6151787f58698"
vary
Accept-Encoding
content-type
application/javascript
cache-control
max-age=2592000
cf-ray
871173596b0b6848-NRT
expires
Wed, 08 May 2024 07:41:50 GMT
bubble.js
resources.infolinks.com/js/1928.005-3.034/
156 KB
46 KB
Script
General
Full URL
https://resources.infolinks.com/js/1928.005-3.034/bubble.js
Requested by
Host: resources.infolinks.com
URL: https://resources.infolinks.com/js/1928.005-3.034/ice.js
Protocol
H2
Security
TLS 1.2, ECDHE_ECDSA, AES_128_GCM
Server
172.66.42.247 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
59ddf97f6e2d2c730808590edffb1c8caf4569dc1f10eb24c374e445911e6841

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:28 GMT
via
1.1 google
content-encoding
gzip
cf-cache-status
HIT
last-modified
Tue, 02 Apr 2024 06:51:09 GMT
server
cloudflare
age
9968
etag
W/"2702f-6151787f58698"
vary
Accept-Encoding
content-type
application/javascript
cache-control
max-age=2592000
cf-ray
871173596b0d6848-NRT
expires
Wed, 08 May 2024 07:21:20 GMT
ima3.js
imasdk.googleapis.com/js/sdkloader/
391 KB
135 KB
Script
General
Full URL
https://imasdk.googleapis.com/js/sdkloader/ima3.js
Requested by
Host: resources.infolinks.com
URL: https://resources.infolinks.com/js/1928.005-3.034/ice.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2404:6800:4004:81e::200a , Australia, ASN15169 (GOOGLE, US),
Reverse DNS
Software
sffe /
Resource Hash
341a0f72628069854a7c3a9954163169e7b1c9120886d72b7f1fbbf477898fca
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:28 GMT
content-encoding
gzip
x-content-type-options
nosniff
server
sffe
cross-origin-opener-policy
same-origin; report-to="ads-doubleclick-instream-static"
vary
Accept-Encoding
report-to
{"group":"ads-doubleclick-instream-static","max_age":2592000,"endpoints":[{"url":"https://csp.withgoogle.com/csp/report-to/ads-doubleclick-instream-static"}]}
content-type
text/javascript
cache-control
private, max-age=900, stale-while-revalidate=3600
cross-origin-resource-policy
cross-origin
accept-ranges
bytes
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
137372
x-xss-protection
0
expires
Mon, 08 Apr 2024 10:07:28 GMT
visit
www.trustedsite.com/rpc/tmjs/oncozine.com/
Redirect Chain
  • https://www.trustedsite.com/rpc/tmjs/oncozine.com/visit?rand=1712570848231
  • https://www.trustedsite.com/rpc/tmjs/oncozine.com/visit?rand=1712570848231&hash=1712570848609
6 B
949 B
Script
General
Full URL
https://www.trustedsite.com/rpc/tmjs/oncozine.com/visit?rand=1712570848231&hash=1712570848609
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Server
52.38.207.187 Boardman, United States, ASN16509 (AMAZON-02, US),
Reverse DNS
ec2-52-38-207-187.us-west-2.compute.amazonaws.com
Software
Apache /
Resource Hash
a4aa9f775af34f63386d8b4d8a14fce2225c317c3f93cbafdeb5a8524eb542a1
Security Headers
Name Value
Strict-Transport-Security max-age=31536000; includeSubDomains
X-Content-Type-Options nosniff

Request headers

accept-language
jp-JP,jp;q=0.9
Referer
https://www.oncozine.com/
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36

Response headers

date
Mon, 08 Apr 2024 10:07:28 GMT
strict-transport-security
max-age=31536000; includeSubDomains
x-content-type-options
nosniff
referrer-policy
strict-origin-when-cross-origin
content-encoding
gzip
server
Apache
content-security-policy-report-only
report-uri https://52723791ca12811bfedec52ea4c44290.report-uri.com/r/d/csp/reportOnly; default-src 'self'; script-src * 'unsafe-inline' 'unsafe-eval'; script-src-elem * 'unsafe-inline'; script-src-attr 'unsafe-inline'; style-src 'self' 'unsafe-inline'; style-src-elem * 'unsafe-inline'; style-src-attr 'self' 'unsafe-inline'; img-src * data:; font-src * data:; connect-src *; media-src * blob:; object-src 'none'; frame-src *; frame-ancestors *; form-action 'self'
content-type
text/javascript; charset=utf-8
content-length
26

Redirect headers

date
Mon, 08 Apr 2024 10:07:28 GMT
strict-transport-security
max-age=31536000; includeSubDomains
x-content-type-options
nosniff
referrer-policy
strict-origin-when-cross-origin
server
Apache
content-security-policy-report-only
report-uri https://52723791ca12811bfedec52ea4c44290.report-uri.com/r/d/csp/reportOnly; default-src 'self'; script-src * 'unsafe-inline' 'unsafe-eval'; script-src-elem * 'unsafe-inline'; script-src-attr 'unsafe-inline'; style-src 'self' 'unsafe-inline'; style-src-elem * 'unsafe-inline'; style-src-attr 'self' 'unsafe-inline'; img-src * data:; font-src * data:; connect-src *; media-src * blob:; object-src 'none'; frame-src *; frame-ancestors *; form-action 'self'
content-type
text/html; charset=utf-8
location
https://www.trustedsite.com/rpc/tmjs/oncozine.com/visit?rand=1712570848231&hash=1712570848609
x-robots-tag
noindex, nofollow
content-length
131
similar-sponsored
www.trendmd.com/journals/61664/ Frame
0
0
Preflight
General
Full URL
https://www.trendmd.com/journals/61664/similar-sponsored?url=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&title=U.S.+FDA+approves+Phase+3+Study+Design+for+Zilovertamab+in+the+Treatment+of+Mantle+Cell+Lymphoma+-+Onco%27Zine&authors=Editorial+Team+et+al.&publication_year=&publication_month=&offset=0&boostedRecommendationsLimit=1&recommendationsType=both&numberOfRecommendations=10&sponsoredLimit=5&titleSize=normal&fontSize=14&titleWording=We+recommend&logoStyle=faded&columns=2&conditionalLoading=Always+load
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
172.67.159.150 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash

Request headers

Accept
*/*
Access-Control-Request-Headers
trendmd-widget-version
Access-Control-Request-Method
GET
Origin
https://www.oncozine.com
Sec-Fetch-Mode
cors
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36

Response headers

access-control-allow-credentials
true
access-control-allow-headers
trendmd-widget-version
access-control-allow-methods
GET, OPTIONS
access-control-allow-origin
https://www.oncozine.com
access-control-expose-headers
Trendmd-Article
access-control-max-age
1728000
alt-svc
h3=":443"; ma=86400
cache-control
no-transform
cf-cache-status
DYNAMIC
cf-ray
871173598d426869-NRT
content-length
7
content-type
text/plain; charset=utf-8
date
Mon, 08 Apr 2024 10:07:28 GMT
nel
{"success_fraction":0,"report_to":"cf-nel","max_age":604800}
report-to
{"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=muM5Iq%2Fnm6jyeFi5WROATPw1OnvXr2KFHH9bAoxRMIIf5wX8EIM8XooVhj6t%2FZuMOmRTS5ACIEAEoPGxCHKNCgb2MI383%2F7H6tpXckeKzZisC6mIP4Ct18gzgqObjeE7v9o%3D"}],"group":"cf-nel","max_age":604800}
server
cloudflare
vary
origin
similar-nonsponsored
cc.trendmd.co/journals/61664/ Frame
0
0
Preflight
General
Full URL
https://cc.trendmd.co/journals/61664/similar-nonsponsored?url=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&title=U.S.+FDA+approves+Phase+3+Study+Design+for+Zilovertamab+in+the+Treatment+of+Mantle+Cell+Lymphoma+-+Onco%27Zine&authors=Editorial+Team+et+al.&publication_year=&publication_month=&offset=0&boostedRecommendationsLimit=1&recommendationsType=both&numberOfRecommendations=10&sponsoredLimit=5&titleSize=normal&fontSize=14&titleWording=We+recommend&logoStyle=faded&columns=2&conditionalLoading=Always+load&timestamp=2024-04-08T02%3A15%3A11.503Z
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
172.67.204.94 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash

Request headers

Accept
*/*
Access-Control-Request-Headers
trendmd-widget-version
Access-Control-Request-Method
GET
Origin
https://www.oncozine.com
Sec-Fetch-Mode
cors
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36

Response headers

access-control-allow-credentials
true
access-control-allow-headers
trendmd-widget-version
access-control-allow-methods
GET, OPTIONS
access-control-allow-origin
https://www.oncozine.com
access-control-expose-headers
Trendmd-Article
access-control-max-age
1728000
alt-svc
h3=":443"; ma=86400
cache-control
max-age=604800 public
cf-cache-status
DYNAMIC
cf-ray
87117359bfd5afd6-NRT
content-length
7
content-type
text/plain; charset=utf-8
date
Mon, 08 Apr 2024 10:07:28 GMT
expires
Mon, 15 Apr 2024 10:07:28 GMT
nel
{"success_fraction":0,"report_to":"cf-nel","max_age":604800}
report-to
{"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=D1INRV5VsAMO1Ju3vsUSHX4jSdMcLDU4SgYUj8nrlMHJ5VWxkM6gtOHdxf5sYsZeAralSM%2B%2FAW9UTldwrzfVwqr%2FPM40uAWCuLGWAYgj5a7U0leJc9SEAyjSW23OFMm3"}],"group":"cf-nel","max_age":604800}
server
cloudflare
vary
origin
similar-sponsored
www.trendmd.com/journals/61664/
12 KB
3 KB
Fetch
General
Full URL
https://www.trendmd.com/journals/61664/similar-sponsored?url=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&title=U.S.+FDA+approves+Phase+3+Study+Design+for+Zilovertamab+in+the+Treatment+of+Mantle+Cell+Lymphoma+-+Onco%27Zine&authors=Editorial+Team+et+al.&publication_year=&publication_month=&offset=0&boostedRecommendationsLimit=1&recommendationsType=both&numberOfRecommendations=10&sponsoredLimit=5&titleSize=normal&fontSize=14&titleWording=We+recommend&logoStyle=faded&columns=2&conditionalLoading=Always+load
Requested by
Host: js.trendmd.com
URL: https://js.trendmd.com/trendmd.min.js
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
172.67.159.150 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
77a0373286e15fb76ba0df69196ebe0bea60ee51996197d5a5559a73fdf779e9
Security Headers
Name Value
X-Frame-Options SAMEORIGIN
X-Xss-Protection 1; mode=block

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
trendmd-widget-version
3.140.0
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:28 GMT
content-encoding
gzip
cf-cache-status
DYNAMIC
nel
{"success_fraction":0,"report_to":"cf-nel","max_age":604800}
alt-svc
h3=":443"; ma=86400
x-xss-protection
1; mode=block
trendmd-article
id=0a9092d6-c4fa-4485-8db8-0e3d89096301, abstract=8436, meta_dated, missing_meta
server
cloudflare
x-frame-options
SAMEORIGIN
access-control-max-age
1728000
access-control-allow-methods
GET, OPTIONS
content-type
text/html; charset=utf-8
access-control-allow-origin
https://www.oncozine.com
access-control-expose-headers
Trendmd-Article
cache-control
no-transform,no-store
access-control-allow-credentials
true
vary
origin,accept-encoding
report-to
{"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=pvt9Lh6Vb6e6nbF6KJofgsfss3HvTP01CkFxOZ9B3FKHTftl6o7LO7Cob6J3yPj2wzljV8HLvmafx71kk9fKyKeVLyfHkeMkYjl7IqKwr8O3uJlXJhRIFYDqScYHGQQf2zg%3D"}],"group":"cf-nel","max_age":604800}
cf-ray
8711735abf4cf5e1-NRT
access-control-allow-headers
trendmd-widget-version
similar-nonsponsored
cc.trendmd.co/journals/61664/
12 KB
3 KB
Fetch
General
Full URL
https://cc.trendmd.co/journals/61664/similar-nonsponsored?url=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&title=U.S.+FDA+approves+Phase+3+Study+Design+for+Zilovertamab+in+the+Treatment+of+Mantle+Cell+Lymphoma+-+Onco%27Zine&authors=Editorial+Team+et+al.&publication_year=&publication_month=&offset=0&boostedRecommendationsLimit=1&recommendationsType=both&numberOfRecommendations=10&sponsoredLimit=5&titleSize=normal&fontSize=14&titleWording=We+recommend&logoStyle=faded&columns=2&conditionalLoading=Always+load&timestamp=2024-04-08T02%3A15%3A11.503Z
Requested by
Host: js.trendmd.com
URL: https://js.trendmd.com/trendmd.min.js
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
172.67.204.94 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
a8db9ac07e33bb7306cda5b1825480572f3754e834af1fb00d60a315aa634181
Security Headers
Name Value
X-Frame-Options SAMEORIGIN
X-Xss-Protection 1; mode=block

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
trendmd-widget-version
3.140.0
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:28 GMT
content-encoding
br
cf-cache-status
BYPASS
nel
{"success_fraction":0,"report_to":"cf-nel","max_age":604800}
alt-svc
h3=":443"; ma=86400
x-xss-protection
1; mode=block
trendmd-article
id=0a9092d6-c4fa-4485-8db8-0e3d89096301, abstract=8436, meta_dated, missing_meta
server
cloudflare
x-frame-options
SAMEORIGIN
access-control-max-age
1728000
access-control-allow-methods
GET, OPTIONS
content-type
text/html; charset=utf-8
access-control-allow-origin
https://www.oncozine.com
access-control-expose-headers
Trendmd-Article
cache-control
max-age=604800, public
access-control-allow-credentials
true
vary
origin,accept-encoding
report-to
{"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=ANzZHVyEHYHhzzCdSAHt1nIIeNok9Lo3LfbPkz6hNxlGMl8OG7dm5PObfW0sKBq7wtx8XvBCF%2F5UL7%2Be5E8Au6gDDfCw%2FKk2x0uF59zt%2FZGaa2ABDAUaw0LzbvqxgStG"}],"group":"cf-nel","max_age":604800}
cf-ray
8711735afa9b80ef-NRT
access-control-allow-headers
trendmd-widget-version
expires
Mon, 15 Apr 2024 10:07:28 GMT
trendmd.min.css
css.trendmd.com/
11 KB
2 KB
Stylesheet
General
Full URL
https://css.trendmd.com/trendmd.min.css
Requested by
Host: js.trendmd.com
URL: https://js.trendmd.com/trendmd.min.js
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
172.67.159.150 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
c8ec28113135035734a3230ac73a28e7db75133884fe421976821c8251d0b19c

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:28 GMT
content-encoding
br
cf-cache-status
HIT
last-modified
Thu, 21 Mar 2024 10:53:34 GMT
nel
{"success_fraction":0,"report_to":"cf-nel","max_age":604800}
server
cloudflare
age
40674
etag
W/"65fc11ae-2b89"
vary
Accept-Encoding
report-to
{"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=0Dasa0e3H8%2FeM0Gkiw4C8Ysu%2BlMy5VVq6ptr%2BVNbFzz1NDB%2Fie4NOFO62z4jPrEm%2FSbbTeONsYYJsq%2BwAzlIm6PEiNWqUBPmLqjUiutusmovGmwq7G1pkVbgkwx4FK1uqJA%3D"}],"group":"cf-nel","max_age":604800}
content-type
text/css
access-control-allow-origin
*
cache-control
public, max-age=86400, must-revalidate
cf-ray
87117359afe4f609-NRT
alt-svc
h3=":443"; ma=86400
getads.htm
rt3073.infolinks.com/action/
135 B
288 B
Script
General
Full URL
https://rt3073.infolinks.com/action/getads.htm?hks=%5B%7B%22lid%22%3A%22d_IL_INSEARCH%22%2C%22bdc%22%3A1%2C%22prod_t%22%3A%22d%22%2C%22garc%22%3A0%2C%22sdata%22%3A%22news%22%2C%22scs%22%3A%22P_bXhU4yjr%22%7D%5D&rid=4099d07b-b80b-40ba-aad4-a5607e6028ba&jsv=1928.005-3.034&sr=800X600&rts=1712570848262&cfv=-1&cb=getAdsResponse&os=Windows&ov=10&br=Chrome&bv=123.0.0.0&dv=p&ce=t&purl=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&tzo=%2B0900&c=c&strg=true&sua=%7B%22architecture%22%3A%22x86%22%2C%22bitness%22%3A%2264%22%2C%22fullVersionList%22%3A%5B%7B%22brand%22%3A%22Google%20Chrome%22%2C%22version%22%3A%22123.0.6312.105%22%7D%2C%7B%22brand%22%3A%22Not%3AA-Brand%22%2C%22version%22%3A%228.0.0.0%22%7D%2C%7B%22brand%22%3A%22Chromium%22%2C%22version%22%3A%22123.0.6312.105%22%7D%5D%2C%22mobile%22%3Afalse%2C%22model%22%3A%22%22%2C%22platform%22%3A%22Win32%22%2C%22platformVersion%22%3A%2210.0.0%22%2C%22uaFullVersion%22%3A%22123.0.6312.105%22%7D&rsd=u9IklIZB1IVVlM2zaB4DjV2LnXa1bkHKXNDkLeP-zImX8q7Z_SgLBrWLPpn2pj0cwAy1_qwlFjiq0DAz-1fgj-EKPtpE0tDchfFFlZfrdMYbweLyL0AoOT5XGG2sHEol1GvQOH-pMjHOFotz8ItxIoaH4ys8zn0l&rsk=96&rcs=qPSdLrwuxU8hIsU2pyg8Tw&cuid=d26e5339-8b70-486f-8a62-c1b4e2caaa26&hbnr=false
Requested by
Host: resources.infolinks.com
URL: https://resources.infolinks.com/js/1928.005-3.034/ice.js
Protocol
H2
Security
TLS 1.2, ECDHE_ECDSA, AES_128_GCM
Server
172.66.42.247 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
65a8734dc9d9d34797ca6a1817b182de378fcb623b54cc5dc533fbf8c7f7bcce

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

pragma
no-cache
date
Mon, 08 Apr 2024 10:07:28 GMT
content-encoding
gzip
cf-cache-status
DYNAMIC
server
cloudflare
vary
Origin, Access-Control-Request-Method, Access-Control-Request-Headers
p3p
CP="NON DSP NID OUR COR"
content-language
jp-JP
content-type
text/html;charset=UTF-8
cache-control
no-cache,no-store
cf-ray
87117359ab5a6848-NRT
expires
Thu, 01 Jan 1970 00:00:00 GMT
in_text.js
resources.infolinks.com/js/1928.005-3.034/
10 KB
4 KB
Script
General
Full URL
https://resources.infolinks.com/js/1928.005-3.034/in_text.js
Requested by
Host: resources.infolinks.com
URL: https://resources.infolinks.com/js/1928.005-3.034/ice.js
Protocol
H2
Security
TLS 1.2, ECDHE_ECDSA, AES_128_GCM
Server
172.66.42.247 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
d2a5cad8642da06458b2c19709066f9c627a4d351384dc8bd8a7f97ff3e18e83

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:28 GMT
via
1.1 google
content-encoding
gzip
cf-cache-status
HIT
last-modified
Tue, 02 Apr 2024 06:51:09 GMT
server
cloudflare
age
3637
etag
W/"295a-6151787f51938"
vary
Accept-Encoding
content-type
application/javascript
cache-control
max-age=2592000
cf-ray
87117359ab6b6848-NRT
expires
Wed, 08 May 2024 09:06:51 GMT
loader.gif
resources.infolinks.com/static/skins/
962 B
1 KB
Image
General
Full URL
https://resources.infolinks.com/static/skins/loader.gif
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.2, ECDHE_ECDSA, AES_128_GCM
Server
172.66.42.247 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
e3b8ee13d35110d7006bc5c5147ee0a0c6c3e1f26b2f246b8d5e57edf4f6b97b

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:28 GMT
via
1.1 google
cf-cache-status
HIT
age
5710
cf-polished
origSize=1631, status=webp_bigger
content-length
962
cf-bgj
imgq:85,h2pri
last-modified
Mon, 20 Mar 2023 11:38:01 GMT
server
cloudflare
etag
"65f-5f7535bfc565e"
vary
Accept-Encoding
content-type
image/gif
cache-control
max-age=2592000
accept-ranges
bytes
cf-ray
8711735a1be36848-NRT
expires
Wed, 08 May 2024 08:32:18 GMT
loader-bg.png
resources.infolinks.com/static/skins/
902 B
1 KB
Image
General
Full URL
https://resources.infolinks.com/static/skins/loader-bg.png
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.2, ECDHE_ECDSA, AES_128_GCM
Server
172.66.42.247 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
c5ddb995fe37710a4be439e4e3f45016cd7b7ecfa3423a29e4f4f4dcce63efff

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:28 GMT
via
1.1 google
cf-cache-status
HIT
age
12746
cf-polished
origFmt=png, origSize=1488
content-disposition
inline; filename="loader-bg.webp"
content-length
902
cf-bgj
imgq:85,h2pri
last-modified
Mon, 20 Mar 2023 11:38:01 GMT
server
cloudflare
etag
"5d0-5f7535bfcac4e"
vary
Accept
content-type
image/webp
cache-control
max-age=2592000
accept-ranges
bytes
cf-ray
8711735a1be96848-NRT
expires
Wed, 08 May 2024 06:35:02 GMT
ima_ppub_config
securepubads.g.doubleclick.net/pagead/
12 B
556 B
XHR
General
Full URL
https://securepubads.g.doubleclick.net/pagead/ima_ppub_config?ippd=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F
Requested by
Host: imasdk.googleapis.com
URL: https://imasdk.googleapis.com/js/sdkloader/ima3.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2404:6800:4004:821::2002 , Australia, ASN15169 (GOOGLE, US),
Reverse DNS
Software
cafe /
Resource Hash
797e3dc8a48bf4fe78ba892d5e966be12cef8bef05dc91043d6421768de0b5c0
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:28 GMT
content-encoding
br
x-content-type-options
nosniff
server
cafe
content-type
application/json; charset=UTF-8
access-control-allow-origin
*
p3p
policyref="https://googleads.g.doubleclick.net/pagead/gcn_p3p_.xml", CP="CURa ADMa DEVa TAIo PSAo PSDo OUR IND UNI PUR INT DEM STA PRE COM NAV OTC NOI DSP COR"
cache-control
private, max-age=900, stale-while-revalidate=3600
cross-origin-resource-policy
cross-origin
content-disposition
attachment; filename="f.txt"
timing-allow-origin
*
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
15
x-xss-protection
0
expires
Mon, 08 Apr 2024 10:07:28 GMT
vidice.js
resources.infolinks.com/js/vidice/4.1/
372 KB
98 KB
Script
General
Full URL
https://resources.infolinks.com/js/vidice/4.1/vidice.js
Requested by
Host: resources.infolinks.com
URL: https://resources.infolinks.com/js/1928.005-3.034/ice.js
Protocol
H2
Security
TLS 1.2, ECDHE_ECDSA, AES_128_GCM
Server
172.66.42.247 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
0d0fd41a302491651608058cdb5be0101ba8c7a5cdd316365227d5e81e9ff354

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:28 GMT
via
1.1 google
content-encoding
gzip
cf-cache-status
HIT
last-modified
Mon, 29 Jan 2024 10:40:04 GMT
server
cloudflare
age
8992
etag
W/"5d1e7-6101344befaf6"
vary
Accept-Encoding
content-type
application/javascript
cache-control
max-age=2592000
cf-ray
8711735b0cc56848-NRT
expires
Wed, 08 May 2024 07:37:36 GMT
0a9092d6-c4fa-4485-8db8-0e3d89096301
www.trendmd.com/journals/61664/articles/ Frame
0
0
Preflight
General
Full URL
https://www.trendmd.com/journals/61664/articles/0a9092d6-c4fa-4485-8db8-0e3d89096301
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
172.67.159.150 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash

Request headers

Accept
*/*
Access-Control-Request-Headers
content-type,trendmd-widget-version
Access-Control-Request-Method
PUT
Origin
https://www.oncozine.com
Sec-Fetch-Mode
cors
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36

Response headers

access-control-allow-credentials
true
access-control-allow-headers
trendmd-widget-version, content-type
access-control-allow-methods
PUT, PATCH, OPTIONS
access-control-allow-origin
https://www.oncozine.com
access-control-max-age
1728000
alt-svc
h3=":443"; ma=86400
cache-control
no-cache
cf-cache-status
DYNAMIC
cf-ray
8711735c787d6869-NRT
date
Mon, 08 Apr 2024 10:07:28 GMT
nel
{"success_fraction":0,"report_to":"cf-nel","max_age":604800}
report-to
{"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=TlZSoUOMH8GSxCGR0Dcv%2B3O5fY1RSEaNYLZ%2BOI%2BlECucJwFlha6%2FJ0mcZPTStR7Q1zgEFzBLIW%2Fh9Ahrc%2FAO739G7Az3Qb%2FfA9hhLq8SbMOl2gCy7DAEQ%2BZa6%2FKP0RSwxT8%3D"}],"group":"cf-nel","max_age":604800}
server
cloudflare
vary
origin
0a9092d6-c4fa-4485-8db8-0e3d89096301
www.trendmd.com/journals/61664/articles/
0
0
Fetch
General
Full URL
https://www.trendmd.com/journals/61664/articles/0a9092d6-c4fa-4485-8db8-0e3d89096301
Requested by
Host: js.trendmd.com
URL: https://js.trendmd.com/trendmd.min.js
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
172.67.159.150 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Frame-Options SAMEORIGIN
X-Xss-Protection 1; mode=block

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
content-type
application/json
trendmd-widget-version
3.140.0
Referer
https://www.oncozine.com/
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:29 GMT
x-content-type-options
nosniff
cf-cache-status
DYNAMIC
nel
{"success_fraction":0,"report_to":"cf-nel","max_age":604800}
alt-svc
h3=":443"; ma=86400
x-xss-protection
1; mode=block
server
cloudflare
x-frame-options
SAMEORIGIN
access-control-max-age
1728000
access-control-allow-methods
PUT, PATCH, OPTIONS
content-type
application/json; charset=utf-8
access-control-allow-origin
https://www.oncozine.com
vary
origin,accept-encoding
access-control-allow-credentials
true
cache-control
no-cache
report-to
{"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=b%2FNRdSDWlKC30XTXv6RdtohMxQWNWEST8WuGi7EJ0tmwwi%2F3z4nbDnff7WmjlD1JqlVGJ0N2Nqdcy%2BVcag7s2kvXqF%2BtuGm8DK7miPbaGnM6vMl%2Fr2WQRXznXAv3VEV7ajE%3D"}],"group":"cf-nel","max_age":604800}
cf-ray
8711735d99b76869-NRT
access-control-allow-headers
trendmd-widget-version
external.png
css.trendmd.com/
180 B
651 B
Image
General
Full URL
https://css.trendmd.com/external.png
Requested by
Host: css.trendmd.com
URL: https://css.trendmd.com/trendmd.min.css
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
172.67.159.150 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
c6f60d401c8d4c88e686254140f1bc9abf6e736358b2b32751b99dd3ae50542d

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://css.trendmd.com/trendmd.min.css
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:29 GMT
cf-cache-status
HIT
nel
{"success_fraction":0,"report_to":"cf-nel","max_age":604800}
age
47277
alt-svc
h3=":443"; ma=86400
content-length
180
last-modified
Thu, 21 Mar 2024 10:53:34 GMT
server
cloudflare
etag
"65fc11ae-b4"
vary
Accept-Encoding
report-to
{"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=24M5i0onjZQ5RMZV5XA7RCmuoqD5%2B190PiltHyvbFF0hFeHIfY1jCfKA7MDz18YLbEROxRJMzxl7bzjDyso%2BM9aDO0BDr%2BD6lrF1j0VcPnHwaViuGF6PRvVbYtJMy%2BVG9nA%3D"}],"group":"cf-nel","max_age":604800}
content-type
image/png
access-control-allow-origin
*
cache-control
public, max-age=86400, must-revalidate
accept-ranges
bytes
cf-ray
8711735e3dedf609-NRT
settings.png
css.trendmd.com/
855 B
1 KB
Image
General
Full URL
https://css.trendmd.com/settings.png
Requested by
Host: css.trendmd.com
URL: https://css.trendmd.com/trendmd.min.css
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
172.67.159.150 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
bda03fc08bf924138fff9ba3b7b37181e9baf658626d8f68025d89bff8a8f385

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://css.trendmd.com/trendmd.min.css
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:29 GMT
cf-cache-status
HIT
nel
{"success_fraction":0,"report_to":"cf-nel","max_age":604800}
age
47277
alt-svc
h3=":443"; ma=86400
content-length
855
last-modified
Thu, 21 Mar 2024 10:53:34 GMT
server
cloudflare
etag
"65fc11ae-357"
vary
Accept-Encoding
report-to
{"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=BL2XD%2FQEwm5sV%2FvLojVgvfiIuY%2BebF5WFdRr0JLl2ZOGZRTJmB0agXAz9xOW7FhhvbT7wTCBgo9xbHAobC%2FkaqAIAAofmyZMZ3kWAyPOUqoCnOb%2BLpk36zY3vDBLvTgQhMA%3D"}],"group":"cf-nel","max_age":604800}
content-type
image/png
access-control-allow-origin
*
cache-control
public, max-age=86400, must-revalidate
accept-ranges
bytes
cf-ray
8711735e3deff609-NRT
js
www.googletagmanager.com/gtag/
245 KB
87 KB
Script
General
Full URL
https://www.googletagmanager.com/gtag/js?id=G-G5TCNFJCYP
Requested by
Host: js.trendmd.com
URL: https://js.trendmd.com/trendmd.min.js
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
172.217.175.72 , United States, ASN15169 (GOOGLE, US),
Reverse DNS
nrt20s20-in-f8.1e100.net
Software
Google Tag Manager /
Resource Hash
21fd5d03a93f32ace7bbbb811c710dfca8c39a6e0e04704b0b3607222864c2f2
Security Headers
Name Value
Strict-Transport-Security max-age=31536000; includeSubDomains
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:29 GMT
content-encoding
br
strict-transport-security
max-age=31536000; includeSubDomains
server
Google Tag Manager
vary
Accept-Encoding
content-type
application/javascript; charset=UTF-8
access-control-allow-origin
*
cache-control
private, max-age=900
access-control-allow-credentials
true
cross-origin-resource-policy
cross-origin
access-control-allow-headers
Cache-Control
content-length
88672
x-xss-protection
0
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
expires
Mon, 08 Apr 2024 10:07:29 GMT
js
www.googletagmanager.com/gtag/
245 KB
87 KB
Script
General
Full URL
https://www.googletagmanager.com/gtag/js?id=G-G5TCNFJCYP&l=dataLayer&cx=c
Requested by
Host: www.googletagmanager.com
URL: https://www.googletagmanager.com/gtag/js?id=G-PGDBN4WRNY
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
172.217.175.72 , United States, ASN15169 (GOOGLE, US),
Reverse DNS
nrt20s20-in-f8.1e100.net
Software
Google Tag Manager /
Resource Hash
18d97a5807aada53dd6fb16c4e132b2167e8d9d5f27c8cf6b8c6333758a62cd6
Security Headers
Name Value
Strict-Transport-Security max-age=31536000; includeSubDomains
X-Xss-Protection 0

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:29 GMT
content-encoding
br
strict-transport-security
max-age=31536000; includeSubDomains
server
Google Tag Manager
vary
Accept-Encoding
content-type
application/javascript; charset=UTF-8
access-control-allow-origin
*
cache-control
private, max-age=900
access-control-allow-credentials
true
cross-origin-resource-policy
cross-origin
access-control-allow-headers
Cache-Control
content-length
88671
x-xss-protection
0
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
expires
Mon, 08 Apr 2024 10:07:29 GMT
events
academia.trendmd.com/ Frame
0
0
Preflight
General
Full URL
https://academia.trendmd.com/events
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
172.67.159.150 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash

Request headers

Accept
*/*
Access-Control-Request-Headers
content-type,trendmd-widget-version
Access-Control-Request-Method
POST
Origin
https://www.oncozine.com
Sec-Fetch-Mode
cors
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36

Response headers

access-control-allow-credentials
true
access-control-allow-headers
content-type, trendmd-widget-version
access-control-allow-methods
POST
access-control-allow-origin
https://www.oncozine.com
access-control-max-age
1728000
alt-svc
h3=":443"; ma=86400
cache-control
no-cache
cf-cache-status
DYNAMIC
cf-ray
8711735e4a526869-NRT
content-type
text/plain; charset=utf-8
date
Mon, 08 Apr 2024 10:07:29 GMT
nel
{"success_fraction":0,"report_to":"cf-nel","max_age":604800}
report-to
{"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=02ZZmaKzgMJAzxUhu0KoMqXWvMGQwuIC2EuE35sccM9fcusBnpe22KNNIQ0ojRnpSq7aUst8J%2BvKbgyJTdDzpc72KyPWbvMyjVggcLBntkcFA3zohQDbg7wV0ywIXxr6txbuY3umuA%3D%3D"}],"group":"cf-nel","max_age":604800}
server
cloudflare
vary
origin,accept-encoding
events
academia.trendmd.com/
15 B
455 B
Fetch
General
Full URL
https://academia.trendmd.com/events
Requested by
Host: js.trendmd.com
URL: https://js.trendmd.com/trendmd.min.js
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
172.67.159.150 , United States, ASN13335 (CLOUDFLARENET, US),
Reverse DNS
Software
cloudflare /
Resource Hash
3d23d39a30bb7323f8ccfd64c52cf286138fba4f83e78f7edcf66703b7c23aaa

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
content-type
application/json
trendmd-widget-version
3.140.0
Referer
https://www.oncozine.com/
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:29 GMT
cf-cache-status
DYNAMIC
nel
{"success_fraction":0,"report_to":"cf-nel","max_age":604800}
server
cloudflare
vary
origin
report-to
{"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=iodvryyY7BG%2B2AgpqxRsQla4cfJMP61w3weUOR0RNfDthoD3zJL9CeGiAfmJc7TbyWSXrLsCOsoZ0RLjIk3YlPMfE%2BB6aiPBHjg9qN34TMKmy9nVcLbuM8nRi5Ftj9EgJwJI2TrpZw%3D%3D"}],"group":"cf-nel","max_age":604800}
content-type
application/json; charset=utf-8
access-control-allow-origin
https://www.oncozine.com
cache-control
no-cache
access-control-allow-credentials
true
cf-ray
8711735f7dd9f5e1-NRT
alt-svc
h3=":443"; ma=86400
content-length
15
advert.gif
mc.yandex.ru/metrika/
43 B
263 B
Image
General
Full URL
https://mc.yandex.ru/metrika/advert.gif
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
2a02:6b8::1:119 , Russian Federation, ASN13238 (YANDEX, RU),
Reverse DNS
Software
/
Resource Hash
548f2d6f4d0d820c6c5ffbeffcbd7f0e73193e2932eefe542accc84762deec87
Security Headers
Name Value
Strict-Transport-Security max-age=31536000

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

date
Mon, 08 Apr 2024 10:07:29 GMT
strict-transport-security
max-age=31536000
last-modified
Fri, 05 Apr 2024 08:05:36 GMT
accept-ch
Sec-CH-UA-Bitness, Sec-CH-UA-Arch, Sec-CH-UA-Full-Version, Sec-CH-UA-Mobile, Sec-CH-UA-Model, Sec-CH-UA-Platform-Version, Sec-CH-UA-Full-Version-List, Sec-CH-UA-Platform, Sec-CH-UA, UA-Bitness, UA-Arch, UA-Full-Version, UA-Mobile, UA-Model, UA-Platform-Version, UA-Platform, UA
etag
"660fb0d0-2b"
content-type
image/gif
access-control-allow-origin
*
cache-control
max-age=3600
accept-ranges
bytes
timing-allow-origin
*
content-length
43
expires
Mon, 08 Apr 2024 11:07:29 GMT
96049782
mc.yandex.ru/watch/
447 B
1 KB
Fetch
General
Full URL
https://mc.yandex.ru/watch/96049782?wmode=7&page-url=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&charset=utf-8&uah=chu%0A%22Google%20Chrome%22%3Bv%3D%22123%22%2C%22Not%3AA-Brand%22%3Bv%3D%228%22%2C%22Chromium%22%3Bv%3D%22123%22%0Acha%0Ax86%0Achb%0A64%0Achf%0A123.0.6312.105%0Achl%0A%22Google%20Chrome%22%3Bv%3D%22123.0.6312.105%22%2C%22Not%3AA-Brand%22%3Bv%3D%228.0.0.0%22%2C%22Chromium%22%3Bv%3D%22123.0.6312.105%22%0Achm%0A%3F0%0Achp%0AWin32%0Achv%0A10.0.0&browser-info=pv%3A1%3Avf%3A6q5vo8idyottrxq49hxwzju1r%3Afu%3A0%3Aen%3Autf-8%3Ala%3Aen-US%3Av%3A1290%3Acn%3A1%3Adp%3A0%3Als%3A1086130977016%3Ahid%3A326410407%3Az%3A540%3Ai%3A20240408190729%3Aet%3A1712570849%3Ac%3A1%3Arn%3A608273343%3Arqn%3A1%3Au%3A1712570849291000135%3Aw%3A1600x1113%3As%3A800x600x24%3Ask%3A1%3Afp%3A1621%3Awv%3A2%3Ads%3A0%2C22%2C8%2C6%2C0%2C0%2C%2C1404%2C0%2C%2C%2C%2C1665%3Aco%3A0%3Acpf%3A1%3Ans%3A1712570846031%3Agi%3AR0ExLjEuMjI3MzIwNjg5LjE3MTI1NzA4NDc%3D%3Arqnl%3A1%3Ast%3A1712570849%3At%3AU.S.%20FDA%20approves%20Phase%203%20Study%20Design%20for%20Zilovertamab%20in%20the%20Treatment%20of%20Mantle%20Cell%20Lymphoma%20-%20Onco%27Zine&t=gdpr(14)clc(0-0-0)rqnt(1)eco(21037572)aw(1)rcm(1)cdl(na)ti(1)
Requested by
Host: mc.yandex.ru
URL: https://mc.yandex.ru/metrika/tag.js
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
2a02:6b8::1:119 , Russian Federation, ASN13238 (YANDEX, RU),
Reverse DNS
Software
/
Resource Hash
bec53c14b4c4b7d08a9f1947f7cfca03b54f86f9cdf291d12c03fcd1f9a7657a
Security Headers
Name Value
Strict-Transport-Security max-age=31536000
X-Content-Type-Options nosniff
X-Xss-Protection 1; mode=block

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

pragma
no-cache
date
Mon, 08 Apr 2024 10:07:29 GMT
strict-transport-security
max-age=31536000
x-content-type-options
nosniff
last-modified
Mon, 08-Apr-2024 10:07:29 GMT
accept-ch
Sec-CH-UA-Bitness, Sec-CH-UA-Arch, Sec-CH-UA-Full-Version, Sec-CH-UA-Mobile, Sec-CH-UA-Model, Sec-CH-UA-Platform-Version, Sec-CH-UA-Full-Version-List, Sec-CH-UA-Platform, Sec-CH-UA, UA-Bitness, UA-Arch, UA-Full-Version, UA-Mobile, UA-Model, UA-Platform-Version, UA-Platform, UA
content-type
application/json; charset=utf-8
access-control-allow-origin
https://www.oncozine.com
cache-control
private, no-cache, no-store, must-revalidate, max-age=0
access-control-allow-credentials
true
content-length
447
x-xss-protection
1; mode=block
expires
Mon, 08-Apr-2024 10:07:29 GMT
2-lab3-218x150.jpg
www.oncozine.com/wp-content/uploads/2024/03/
7 KB
8 KB
Image
General
Full URL
https://www.oncozine.com/wp-content/uploads/2024/03/2-lab3-218x150.jpg
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
ccb049c974a0117cf45c9d6ba882cd6d76f3e95c7863029758f891d08f0e69eb

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:30 GMT
expires
Tue, 08 Apr 2025 04:27:23 GMT
last-modified
Sat, 30 Mar 2024 10:49:15 GMT
server
nginx
etag
"6607ee2b-1d08"
content-type
image/jpeg
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
accept-ranges
bytes
content-length
7432
x-cdn-c
all
x-sg-cdn
1
Fotolia_82360489_Subscription_Monthly_M-1-218x150.jpg
www.oncozine.com/wp-content/uploads/2018/04/
9 KB
10 KB
Image
General
Full URL
https://www.oncozine.com/wp-content/uploads/2018/04/Fotolia_82360489_Subscription_Monthly_M-1-218x150.jpg
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
62b6e661596910b769a2a212b3cc094fb709b3c5c074e020fff0e46816fa9a59

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:30 GMT
expires
Tue, 08 Apr 2025 04:27:23 GMT
last-modified
Fri, 28 Jun 2019 07:33:49 GMT
server
nginx
etag
"5d15c2dd-254b"
content-type
image/jpeg
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
accept-ranges
bytes
content-length
9547
x-cdn-c
all
x-sg-cdn
1
sangharsh-lohakare-8o_LkMpo8ug-unsplash-2-218x150.jpg
www.oncozine.com/wp-content/uploads/2024/03/
10 KB
11 KB
Image
General
Full URL
https://www.oncozine.com/wp-content/uploads/2024/03/sangharsh-lohakare-8o_LkMpo8ug-unsplash-2-218x150.jpg
Requested by
Host: www.oncozine.com
URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
34.149.36.179 Kansas City, United States, ASN15169 (GOOGLE, US),
Reverse DNS
179.36.149.34.bc.googleusercontent.com
Software
nginx /
Resource Hash
a6a54132c356fe2a394ff21b8fe1578e7134e7933afe1794b0b5fd376bc2fffd

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

x-proxy-cache
HIT
date
Mon, 08 Apr 2024 10:07:30 GMT
expires
Tue, 08 Apr 2025 04:27:23 GMT
last-modified
Mon, 25 Mar 2024 16:55:48 GMT
server
nginx
etag
"6601ac94-297a"
content-type
image/jpeg
cache-control
max-age=31536000
host-header
8441280b0c35cbc1147f8ba998a563a7
accept-ranges
bytes
content-length
10618
x-cdn-c
all
x-sg-cdn
1
96049782
mc.yandex.ru/webvisor/
0
0

collect
www.google-analytics.com/g/
0
17 B
Ping
General
Full URL
https://www.google-analytics.com/g/collect?v=2&tid=G-PGDBN4WRNY&gtm=45je4430v876608970z8839587796za200&_p=1712570846381&gcd=13l3l3l3l1&npa=0&dma=0&gdid=dZGIzZG&cid=227320689.1712570847&ul=en-us&sr=800x600&uaa=x86&uab=64&uafvl=Google%2520Chrome%3B123.0.6312.105%7CNot%253AA-Brand%3B8.0.0.0%7CChromium%3B123.0.6312.105&uamb=0&uam=&uap=Win32&uapv=10.0.0&uaw=0&pscdl=noapi&_eu=AAAC&_s=3&sid=1712570846&sct=1&seg=1&dl=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&dt=U.S.%20FDA%20approves%20Phase%203%20Study%20Design%20for%20Zilovertamab%20in%20the%20Treatment%20of%20Mantle%20Cell%20Lymphoma%20-%20Onco%27Zine&en=page_view&_et=1310&tfd=6806
Requested by
Host: www.googletagmanager.com
URL: https://www.googletagmanager.com/gtag/js?id=G-PGDBN4WRNY
Protocol
H3
Security
QUIC, , AES_128_GCM
Server
142.250.196.142 , United States, ASN15169 (GOOGLE, US),
Reverse DNS
nrt12s36-in-f14.1e100.net
Software
Golfe2 /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

pragma
no-cache
date
Mon, 08 Apr 2024 10:07:32 GMT
server
Golfe2
content-type
text/plain
access-control-allow-origin
https://www.oncozine.com
cache-control
no-cache, no-store, must-revalidate
access-control-allow-credentials
true
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
0
expires
Fri, 01 Jan 1990 00:00:00 GMT
csi
csi.gstatic.com/
0
234 B
Ping
General
Full URL
https://csi.gstatic.com/csi?v=2&s=pagead&action=csi_pagead&dmc=8&top=1&puid=1~luqsgrg9&c=4282168737799688&e=44759875%2C44759926%2C44759837%2C95329025%2C95329439%2C95329462%2C95329571%2C31081717%2C31061691%2C31061692&ctx=1&met.3=1001.1az_1__1~164.1b0_1~165.1ay_3~166.1ap_c~1032.1gs~326.1gt_1~832.1gw~868.1gw~216.1gr_5~215.1gr_5~843.1gq_6~889.1ha~639.1hi~112.1ii_1
Requested by
Host: pagead2.googlesyndication.com
URL: https://pagead2.googlesyndication.com/pagead/js/r20240403/r20110914/rum_fy2021.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4010:c06::78 -, , ASN (),
Reverse DNS
Software
Golfe2 /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
sec-ch-ua-platform
"Win32"

Response headers

pragma
no-cache
date
Mon, 08 Apr 2024 10:07:33 GMT
last-modified
Wed, 21 Jan 2004 19:51:30 GMT
server
Golfe2
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cross-origin-resource-policy
cross-origin
alt-svc
h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
content-length
0
expires
Fri, 01 Jan 1990 00:00:00 GMT
96049782
mc.yandex.ru/webvisor/
43 B
0
Fetch
General
Full URL
https://mc.yandex.ru/webvisor/96049782?wv-part=1&wv-type=7&wmode=0&wv-hit=326410407&page-url=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&rn=932703163&browser-info=we%3A1%3Aet%3A1712570853%3Aw%3A1600x1113%3Av%3A1290%3Az%3A540%3Ai%3A20240408190733%3Au%3A1712570849291000135%3Avf%3A6q5vo8idyottrxq49hxwzju1r%3Ast%3A1712570853&t=gdpr(14)ti(1)
Requested by
Host: mc.yandex.ru
URL: https://mc.yandex.ru/metrika/tag.js
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
2a02:6b8::1:119 , Russian Federation, ASN13238 (YANDEX, RU),
Reverse DNS
Software
/
Resource Hash
Security Headers
Name Value
Strict-Transport-Security max-age=31536000
X-Xss-Protection 1; mode=block

Request headers

sec-ch-ua
"Google Chrome";v="123", "Not:A-Brand";v="8", "Chromium";v="123"
sec-ch-ua-platform
"Win32"
Referer
https://www.oncozine.com/
accept-language
jp-JP,jp;q=0.9
sec-ch-ua-mobile
?0
User-Agent
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/123.0.0.0 Safari/537.36
Content-Type
text/plain

Response headers

pragma
no-cache
date
Mon, 08 Apr 2024 10:07:33 GMT
strict-transport-security
max-age=31536000
last-modified
Mon, 08-Apr-2024 10:07:33 GMT
content-type
image/gif
access-control-allow-origin
https://www.oncozine.com
cache-control
private, no-cache, no-store, must-revalidate, max-age=0
access-control-allow-credentials
true
content-length
43
x-xss-protection
1; mode=block
expires
Mon, 08-Apr-2024 10:07:33 GMT
/
cloud.tnewstraffic.com/
0
0

96049782
mc.yandex.ru/webvisor/
0
0

96049782
mc.yandex.ru/webvisor/
0
0

/
cloud.tnewstraffic.com/
0
0

/
cloud.tnewstraffic.com/
0
0

/
cloud.tnewstraffic.com/
0
0

/
cloud.tnewstraffic.com/
0
0

/
cloud.tnewstraffic.com/
0
0

Failed requests

These URLs were requested, but there was no response received. You will also see them in the list above.

Domain
mc.yandex.ru
URL
https://mc.yandex.ru/webvisor/96049782?wv-part=1&wv-type=7&wmode=0&wv-hit=326410407&page-url=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&rn=616166850&browser-info=bt%3A1%3Awe%3A1%3Aet%3A1712570853%3Aw%3A1600x1113%3Av%3A1290%3Az%3A540%3Ai%3A20240408190732%3Au%3A1712570849291000135%3Avf%3A6q5vo8idyottrxq49hxwzju1r%3Ast%3A1712570853&t=gdpr(14)ti(1)
Domain
cloud.tnewstraffic.com
URL
https://cloud.tnewstraffic.com/?news&s
Domain
mc.yandex.ru
URL
https://mc.yandex.ru/webvisor/96049782?wv-part=2&wv-type=7&wmode=0&wv-hit=326410407&page-url=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&rn=843221620&browser-info=we%3A1%3Aet%3A1712570854%3Aw%3A1600x1113%3Av%3A1290%3Az%3A540%3Ai%3A20240408190734%3Au%3A1712570849291000135%3Avf%3A6q5vo8idyottrxq49hxwzju1r%3Ast%3A1712570854&t=gdpr(14)ti(1)
Domain
mc.yandex.ru
URL
https://mc.yandex.ru/webvisor/96049782?wv-part=2&wv-type=7&wmode=0&wv-hit=326410407&page-url=https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F&rn=589826909&browser-info=bt%3A1%3Awe%3A1%3Aet%3A1712570854%3Aw%3A1600x1113%3Av%3A1290%3Az%3A540%3Ai%3A20240408190734%3Au%3A1712570849291000135%3Avf%3A6q5vo8idyottrxq49hxwzju1r%3Ast%3A1712570854&t=gdpr(14)ti(1)
Domain
cloud.tnewstraffic.com
URL
https://cloud.tnewstraffic.com/?news&s
Domain
cloud.tnewstraffic.com
URL
https://cloud.tnewstraffic.com/?news&s
Domain
cloud.tnewstraffic.com
URL
https://cloud.tnewstraffic.com/?news&s
Domain
cloud.tnewstraffic.com
URL
https://cloud.tnewstraffic.com/?news&s
Domain
cloud.tnewstraffic.com
URL
https://cloud.tnewstraffic.com/?news&s

Verdicts & Comments Add Verdict or Comment

276 JavaScript Global Variables

These are the non-standard "global" variables defined on the window object. These can be helpful in identifying possible client-side frameworks and code.

object| 0 object| 1 object| 2 object| 3 string| gtm4wp_datalayer_name object| dataLayer string| mi_version boolean| mi_track_user string| mi_no_track_reason object| MonsterInsightsDefaultLocations object| MonsterInsightsLocations object| disableStrs function| __gtagTrackerIsOptedOut undefined| index function| __gtagTrackerOptout function| gaOptout function| __gtagDataLayer function| __gtagTracker object| MonsterInsightsDualTracker function| gtag function| __gaTracker object| monsterinsights_frontend undefined| $ function| jQuery number| is_wp object| _izootoModule object| _izq function| powerpress_pinw object| dataLayer_content function| monsterinsights_forms_record_impression function| monsterinsights_forms_has_class function| monsterinsights_forms_record_conversion function| monsterinsights_forms_load function| monsterinsights_add_bloom_forms_ids function| monsterinsights_find_parent_with_class object| tdBlocksArray function| tdBlock object| tdLocalCache object| td_viewport_interval_list string| td_animation_stack_effect boolean| tds_animation_stack string| td_animation_stack_specific_selectors string| td_animation_stack_general_selectors string| tdc_is_installed string| td_ajax_url string| td_get_template_directory_uri string| tds_snap_menu string| tds_logo_on_sticky string| tds_header_style string| td_please_wait string| td_email_user_pass_incorrect string| td_email_user_incorrect string| td_email_incorrect string| td_user_incorrect string| td_email_user_empty string| td_pass_empty string| td_pass_pattern_incorrect string| td_retype_pass_incorrect string| tds_more_articles_on_post_enable string| tds_more_articles_on_post_time_to_wait number| tds_more_articles_on_post_pages_distance_from_top string| tds_theme_color_site_wide string| tds_smart_sidebar string| tdThemeName string| td_magnific_popup_translation_tPrev string| td_magnific_popup_translation_tNext string| td_magnific_popup_translation_tCounter string| td_magnific_popup_translation_ajax_tError string| td_magnific_popup_translation_image_tError string| tdBlockNonce object| tdDateNamesI18n string| tdb_modal_confirm string| tdb_modal_cancel string| tdb_modal_confirm_alt string| tdb_modal_cancel_alt string| td_ad_background_click_link string| td_ad_background_click_target object| monsterinsights_tracked_video_marks object| monsterinsights_youtube_percentage_tracking_timeouts function| monsterinsights_media_get_id_for_iframe function| monsterinsights_media_record_video_event function| monsterinsights_media_maybe_record_video_progress object| monsterinsights_media_vimeo_plays function| monsterinsights_setup_vimeo_events_for_iframe function| monsterinsights_on_vimeo_load function| monsterinsights_media_init_vimeo_events function| monsterinsights_media_on_youtube_load function| monsterinsights_media_load_youtube_api function| monsterinsights_media_init_youtube_events function| monsterinsights_media_init_html_video_events function| monsterinsights_media_init_video_events function| monsterinsights_media_load function| onYouTubeIframeAPIReady object| google_tag_manager object| google_tag_data object| gaGlobal function| nh string| url function| nV string| url2 function| Q function| _0x53bf function| M string| popURL function| onPopUnderLoaded function| _0x21e5 function| makePopunder function| nU function| nt function| nf function| r object| div object| img undefined| _paq function| ym object| block_tdi_4 object| block_tdi_8 object| block_tdi_11 object| block_tdi_12 number| infolinks_pid string| infolinks_plugin_version string| infolinks_resources boolean| IL_INIT object| $iceboot object| INFOLINKS object| awsmJobsPublic object| container undefined| _izAlt object| _iz object| izConfig object| wpforms_user_journey object| WPFormsUserJourney function| MonsterInsights object| MonsterInsightsObject object| TrendMDProfiling object| trendmdGlobalState object| global object| TrendMD object| TrendMDGTM function| Cookies object| lazySizes object| $jscomp object| tdAnalytics object| tdDetect object| tdViewport object| tdMenu object| tdUtil object| tdAffix function| td_smart_list_dropdown object| td_more_articles_box undefined| td_resize_timer_id function| td_done_resizing function| td_resize_videos function| td_mobile_menu function| td_mobile_menu_toogle function| td_retina function| td_read_site_cookie function| td_set_cookies_life boolean| tdIsScrollingAnimation boolean| td_mouse_wheel_or_touch_moved boolean| td_scroll_to_top_is_visible function| td_events_scroll_scroll_to_top function| td_post_template_6_title function| td_smart_lists_magnific_popup function| td_get_document_width function| td_get_document_height function| td_comments_form_validation object| tdLoadingBox object| tdAjaxSearch string| tdModalImageLastEl object| tdBlocks object| tdLogin object| tdLoginMob object| tdDemoMenu object| tdTrendingNow object| td_history object| tdSmartSidebar object| tdStickyRow object| tdScrollToClass object| tdInfiniteLoader function| Froogaloop object| tdCustomEvents object| tdEvents object| tdHeader object| tdAjaxCount object| tdYoutubePlayers object| tdVimeoPlayers function| td_resize_smartlist_slides function| td_resize_smartlist_sliders_and_update function| td_resize_normal_slide function| td_resize_normal_slide_and_update object| tdPullDown object| td_fps object| tdAnimationScroll object| tdHomepageFull object| tdBackstr object| tdShowVideo object| tdAnimationStack function| td_compute_parallax_background function| td_compute_backstretch_item object| td_backstretch_items object| tdAjaxLoop object| tdWeather object| tdAnimationSprite function| td_date_i18n object| tdSocialSharing function| tdModalImage object| tdAjaxVideoModal object| tdfAjaxFlickr object| tdPopupModal object| tdReadingProgressBar object| tdTabbedContent object| tdConfirm function| Hammer function| $f object| AMP object| addComment object| TrustedSite number| TrustedSite_done object| TrustedSiteInline object| google_js_reporting_queue number| google_srt object| google_persistent_state_async object| google_logging_queue number| tmod object| google_ad_modifications object| ggeac boolean| google_measure_js_timing object| google_reactive_ads_global_state object| adsbygoogle object| google_sa_queue function| google_process_slots number| google_rum_task_id_counter function| google_spfd number| google_unique_id object| google_sv_map string| google_user_agent_client_hint function| _typeof function| _defineProperty number| n object| awsmJobs string| GoogleAnalyticsObject function| ga function| _izooto object| gaplugins object| gaData number| $iceId function| google_sa_impl object| google_rum_config object| google_image_requests number| google_global_correlator object| google_prev_clients object| ampInaboxIframes object| ampInaboxPendingMessages object| _google_rum_ns_ object| bubble object| skins function| Goog_AdSense_Lidar_sendVastEvent function| Goog_AdSense_Lidar_getViewability function| Goog_AdSense_Lidar_getUrlSignalsArray function| Goog_AdSense_Lidar_getUrlSignalsList object| google object| module$exports$google3$javascript$ads$interactivemedia$sdk$clientside$api$companion_ad_selection_settings object| module$exports$google3$javascript$ads$interactivemedia$sdk$clientside$api$ads_rendering_settings object| ima object| module$exports$google3$javascript$ads$interactivemedia$sdk$clientside$api$ad_error object| module$exports$google3$javascript$ads$interactivemedia$sdk$clientside$api$ad_error_event object| module$exports$google3$javascript$ads$interactivemedia$sdk$clientside$api$ad_event object| module$exports$google3$javascript$ads$interactivemedia$sdk$clientside$api$ads_manager_loaded_event object| goog function| ILVideo object| trendmdSentEvents object| Ya object| yaCounter96049782 function| izootoEmailSubcriptionCallBack function| izootoEmailEventsCallback

174 Cookies

Domain/Path Name / Value
www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma Name: logglytrackingsession
Value: 487a864c-dc75-4e5b-a730-ffd7fd2b6db1
www.oncozine.com/ Name: _wpfuj
Value: {"1712570848":"https%3A%2F%2Fwww.oncozine.com%2Fu-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma%2F%7C%23%7CU.S.%20FDA%20approves%20Phase%203%20Study%20Design%20for%20Zilovertamab%20in%20the%20Treatment%20of%20Mantle%20Cell%20Lymphoma%20-%20Onco%5C'Zine%7C%23%7C14566"}
.oncozine.com/ Name: _ga_PGDBN4WRNY
Value: GS1.1.1712570846.1.1.1712570847.0.0.0
.oncozine.com/ Name: _gid
Value: GA1.2.341405600.1712570848
.infolinks.com/ Name: cuid
Value: d26e5339-8b70-486f-8a62-c1b4e2caaa26
.oncozine.com/ Name: _gat_gtag_UA_188673758_1
Value: 1
.oncozine.com/ Name: _gat_UA-188673758-1
Value: 1
.izooto.com/ Name: IZCID
Value: 3b2a7b77-870a-4f47-bd6f-fd4afcc16cd3
.pubmatic.com/ Name: KADUSERCOOKIE
Value: FF0D79E1-DC81-450A-B58D-92B7449448CF
.casalemedia.com/ Name: CMID
Value: ZhPB324sBywAAGHWA.tWggAA
.casalemedia.com/ Name: CMPS
Value: 5533
.casalemedia.com/ Name: CMPRO
Value: 5533
.oncozine.com/ Name: _ga_MW8SS19QHB
Value: GS1.1.1712570847.1.0.1712570847.0.0.0
.oncozine.com/ Name: _ga
Value: GA1.1.227320689.1712570847
.adsrvr.org/ Name: TDID
Value: 03330874-85d5-499e-8987-7cafdb1258cb
.socdm.com/ Name: SOC
Value: ZhPB38Co5s8AAD.3zCEAAAAA
.doubleclick.net/ Name: IDE
Value: AHWqTUm3o9MZCBBCQohYgzTkBErfBGhW6Vt2V0SSTEa6_w9CC4PKQaV_4Gwubs4gnoc
.infolinks.com/ Name: IXUSERCOOKIE
Value: ZhPB324sBywAAGHWA.tWggAA&5533
.adnxs.com/ Name: receive-cookie-deprecation
Value: 1
.doubleclick.net/ Name: test_cookie
Value: CheckForPermission
www.oncozine.com/ Name: trustedsite_visit
Value: 1
.sharethrough.com/ Name: stx_user_id
Value: b04a5e40-4c07-408d-90ff-a08c9b51051b
.smartadserver.com/ Name: pid
Value: 7470683819092459371
.3lift.com/ Name: tluidp
Value: 3776007738295963509464
.3lift.com/ Name: tluid
Value: 3776007738295963509464
.yahoo.com/ Name: A3
Value: d=AQABBODBE2YCEHkquoP4lu4K10Q7vJ9vWQkFEgEBAQETFWYdZmChyyMA_eMAAA&S=AQAAAvqXQuys3YyYKyYYeLkhq04
.infolinks.com/ Name: R1USERCOOKIE
Value: OPTOUT
.infolinks.com/ Name: OXUSERCOOKIE
Value: 214410b6-c4df-4381-9ef1-39eee9600c1f
.infolinks.com/ Name: PUBMUSERCOOKIE
Value: FF0D79E1-DC81-450A-B58D-92B7449448CF
.infolinks.com/ Name: SHTUSERCOOKIE
Value: b04a5e40-4c07-408d-90ff-a08c9b51051b
.infolinks.com/ Name: EQVSERCOOKIE
Value: 7470683819092459371
.advertising.com/ Name: A3
Value: d=AQABBODBE2YCEACipzCZ-UhrOLFO95P3PV0FEgEBAQETFWYdZmChyyMA_eMAAA&S=AQAAAuZPxTvdhxpprn1CUku7gbc
.tapad.com/ Name: TapAd_TS
Value: 1712570848399
.tapad.com/ Name: TapAd_DID
Value: bec542ea-cb2f-4efa-baa5-f34769551905
.infolinks.com/ Name: TPLSERCOOKIE
Value: 3776007738295963509464
.infolinks.com/ Name: VRUSERCOOKIE
Value: y-dv0TGBFE2uLJ03zMJQgoB7LOauSBZ1kC~A
mc.yandex.ru/ Name: yabs-sid
Value: 2031281181712570848
.yandex.ru/ Name: receive-cookie-deprecation
Value: 1
mc.yandex.ru/ Name: bh
Value: EkAiR29vZ2xlIENocm9tZSI7dj0iMTIzIiwgIk5vdDpBLUJyYW5kIjt2PSI4IiwgIkNocm9taXVtIjt2PSIxMjMiKgI/MDoHIldpbjMyIg==
.pubmatic.com/ Name: KRTBCOOKIE_80
Value: 22987-CAESEMiG2sLEngbBoMDfvBIozvQ&KRTB&23025-CAESEMiG2sLEngbBoMDfvBIozvQ&KRTB&23386-CAESEMiG2sLEngbBoMDfvBIozvQ
.pxl.iqm.com/ Name: infolink
Value: MTcxMzc4MDQ0ODQ1OQ==
.pxl.iqm.com/ Name: iqm.retarget.uid
Value: 29642689-546a-4290-8973-dabb9c47e142
.360yield.com/ Name: tuuid
Value: 49404f30-3a6f-4b15-b14f-c5c4f889bc44
.360yield.com/ Name: tuuid_lu
Value: 1712570848
.media.net/ Name: visitor-id
Value: 3555724480032771000V10
.media.net/ Name: data-inf
Value: setstatuscode~~41
.tapad.com/ Name: TapAd_3WAY_SYNCS
Value: 1!2386
.tynt.com/ Name: uid
Value: uNE6HWYTweDfxCwlL273/A==
.infolinks.com/ Name: OUTHUSERCOOKIE
Value: y-HuCKNoNE2uErUKSz..Vt3Ug9I0arJZgp~A
.adkernel.com/ Name: SSPR_40
Value: aHR0cHM6Ly9yb3V0ZXIuaW5mb2xpbmtzLmNvbS9keW4vcW9yYS11c3luYz91aWQ9QTYyNzQxNTMzNjI3MzIxMzA5MTY=
.adkernel.com/ Name: SSPZ
Value: 208912
.adkernel.com/ Name: DSP2F_40
Value: 422028
.adkernel.com/ Name: ADKUID
Value: A6274153362732130916
.infolinks.com/ Name: IQMUS
Value: 29642689-546a-4290-8973-dabb9c47e142
.infolinks.com/ Name: MNETUSERCOOKIE
Value: 3555724480032771000V10
.infolinks.com/ Name: IMDUSERCOOKIE
Value: 49404f30-3a6f-4b15-b14f-c5c4f889bc44
.zemanta.com/ Name: zuid
Value: cPJ5FnBqMQ9efG9P-U74
.amazon-adsystem.com/ Name: ad-id
Value: A7AcUwDLS0-MibGyPuB43PM
.amazon-adsystem.com/ Name: ad-privacy
Value: 0
.infolinks.com/ Name: URUSERCOOKIE
Value: OPTOUT
.infolinks.com/ Name: FRWHUSERCOOKIE
Value: 3384b0479540f911ec97a4b350ce74b5
.simpli.fi/ Name: suid
Value: 6AE8CFED32C6447EA380A6FF4BE49DC7
.tynt.com/ Name: pids
Value: %5B%7B%22p%22%3A%22797f54a72d%22%2C%22f%22%3A1%2C%22ts%22%3A1712570848702%7D%2C%7B%22p%22%3A%22baebe6454b%22%2C%22f%22%3A1%2C%22ts%22%3A1712570848702%7D%2C%7B%22p%22%3A%227912d88d74%22%2C%22f%22%3A1%2C%22ts%22%3A1712570848702%7D%2C%7B%22p%22%3A%2224c05c7b76%22%2C%22f%22%3A1%2C%22ts%22%3A1712570848702%7D%2C%7B%22p%22%3A%22f9a4a8fd15%22%2C%22f%22%3A1%2C%22ts%22%3A1712570848702%7D%2C%7B%22p%22%3A%22008c314e8f%22%2C%22f%22%3A1%2C%22ts%22%3A1712570848702%7D%5D
.yandex.ru/ Name: i
Value: dHetZxSmiRq8UZT6dDxpALPgLPuriJ5mnPw6BoIY97kZgnehfOe2so7V1/SyrhvaXl0EDSR/GBuFM2RHPoJuB1Dsf3c=
.yandex.ru/ Name: yandexuid
Value: 4865671391712570848
.yandex.ru/ Name: yashr
Value: 7706734351712570848
www.trustedsite.com/ Name: AWSALBCORS
Value: bOxdJ0NqUjpzuVG8sXpTNl6qgMBywMU4yr+nWSukIDjLmq3LxdXybAU7t1/cFxkhyxSbu28bq4TMMgT2FMmfNxQpVAUDVfOB/uLTVXIjArm78ctVsxAIZqUzgxyw
.bidswitch.net/ Name: tuuid
Value: 53825eb4-6ef5-4eed-b252-2e758860640f
.bidswitch.net/ Name: c
Value: 1712570848
.bidswitch.net/ Name: tuuid_lu
Value: 1712570848
.quantserve.com/ Name: mc
Value: 6613c1e0-bd1b7-404e4-0d20b
.go.sonobi.com/ Name: __uis
Value: 4ac9cdae-a088-41b8-9c6f-f67055505ae4
.go.sonobi.com/ Name: HAPLB3A
Value: s3597|ZhPB4
.lijit.com/ Name: ljt_reader
Value: IdM_ALZH6jOcZGrgSsOmhqF0
.infolinks.com/ Name: QCUSERCOOKIE
Value: 3y5HnoopE53EehKciy9bmdksE5nEKBKf2Xr4C97J
.infolinks.com/ Name: SONOBIUSERCOOKIE
Value: 4ac9cdae-a088-41b8-9c6f-f67055505ae4
.rfihub.com/ Name: ruds
Value: H4sIAAAAAAAA_-MSNrQ0NzKwMDEwN7EwNLQwMjI1MRHiM9T1yi_0y4pyCSn0cQwCAA4a8IIlAAAA
.rfihub.com/ Name: rud
Value: H4sIAAAAAAAA_-MSNrQ0NzKwMDEwN7EwNLQwMjI1MRHiM9T1yi_0y4pyCSn0cQwCAA4a8IIlAAAA
.infolinks.com/ Name: ZMNUSERCOOKIE
Value: cPJ5FnBqMQ9efG9P-U74
.infolinks.com/ Name: SOVRNUSERCOOKIE
Value: IdM_ALZH6jOcZGrgSsOmhqF0
.rubiconproject.com/ Name: khaos
Value: LUQSGSA9-1C-33P2
.infolinks.com/ Name: ZTUSERCOOKIE
Value: 1972084074811822544
.mgid.com/ Name: lmg_usr
Value: c0896f44-eb81-4512-92f8-511bd4e6f955
.mgid.com/ Name: lmg_r
Value: 13
.disqus.com/ Name: zeta-ssp-user-id
Value: ua-655b14e3-8576-32fd-abcb-0422d6799bed
.bidr.io/ Name: bito
Value: AADQy07MJ4QAABTZTuRLeQ
.bidr.io/ Name: bitoIsSecure
Value: ok
.infolinks.com/ Name: MGIDUSERCOOKIE
Value: c0896f44-eb81-4512-92f8-511bd4e6f955
.33across.com/ Name: 33x_ps
Value: u%3D212550272836114%3As1%3D1712570849233%3Ats%3D1712570849233
.turn.com/ Name: uid
Value: 8265057714819380363
.pubmatic.com/ Name: DPSync3
Value: 1713744000%3A201_245_226%7C1712620800%3A248
.pubmatic.com/ Name: SyncRTB3
Value: 1713398400%3A63%7C1713139200%3A15_223_2%7C1713744000%3A220_217_71_3_107_179_21_214_96_76_266_13_209_233_5_56_264_46_22_254_234_7_54_8_202%7C1713830400%3A35%7C1717718400%3A69
.oncozine.com/ Name: _ym_uid
Value: 1712570849291000135
.oncozine.com/ Name: _ym_d
Value: 1712570849
.adsrvr.org/ Name: TDCPM
Value: CAESFQoGY2FzYWxlEgsI1MHVp7fv6zwQBRIUCgV0YXBhZBILCKjm3Ky37-s8EAUSGAoJYmlkc3dpdGNoEgsIiLG1r7fv6zwQBRIWCgdydWJpY29uEgsI8OKjs7fv6zwQBRIXCghwdWJtYXRpYxILCML977S37-s8EAUYASABKAIyCwji8_Lhze_rPBAFOAFaCHB1Ym1hdGljYAI.
.socdm.com/ Name: SOSYNC
Value: anNvbjp7InB1Ym1hdGljIjoxNzEyNTcwODQ5fQ
.pubmatic.com/ Name: KRTBCOOKIE_377
Value: 6810-03330874-85d5-499e-8987-7cafdb1258cb&KRTB&22918-03330874-85d5-499e-8987-7cafdb1258cb&KRTB&22926-03330874-85d5-499e-8987-7cafdb1258cb&KRTB&23031-03330874-85d5-499e-8987-7cafdb1258cb
.pubmatic.com/ Name: KRTBCOOKIE_656
Value: 12671-ZhPB38Co5s8AAD.3zCEAAAAA&KRTB&23509-ZhPB38Co5s8AAD.3zCEAAAAA&KRTB&23514-ZhPB38Co5s8AAD.3zCEAAAAA&KRTB&23568-ZhPB38Co5s8AAD.3zCEAAAAA
.infolinks.com/ Name: 33AUSERCOOKIE
Value: 212385087416330
.ctnsnet.com/ Name: cid
Value: 7461ffdb24354f518fe695326345da68
.pubmatic.com/ Name: KRTBCOOKIE_1159
Value: 23138-7461ffdb24354f518fe695326345da68&KRTB&23328-7461ffdb24354f518fe695326345da68&KRTB&23427-7461ffdb24354f518fe695326345da68
.quantserve.com/ Name: d
Value: EKMBEgHIK_ijDM_qMA
.ladsp.com/ Name: cr
Value: 1
.pubmatic.com/ Name: KRTBCOOKIE_153
Value: 1923-u1BqYu5XPmGgBD9g71F2Zb1SPmWgVj9jvQQkmP5T&KRTB&19420-u1BqYu5XPmGgBD9g71F2Zb1SPmWgVj9jvQQkmP5T&KRTB&22979-u1BqYu5XPmGgBD9g71F2Zb1SPmWgVj9jvQQkmP5T&KRTB&23462-u1BqYu5XPmGgBD9g71F2Zb1SPmWgVj9jvQQkmP5T
.ladsp.com/ Name: smn_uid
Value: mDP_OyxV7M34fB2GL-bEvBA9TS8x4Bs
.ladsp.com/ Name: lum
Value: CKGxtenrMRIFCAoQ4BI
.pubmatic.com/ Name: KRTBCOOKIE_22
Value: 14911-8265057714819380363&KRTB&23150-8265057714819380363&KRTB&23527-8265057714819380363
.pubmatic.com/ Name: KRTBCOOKIE_629
Value: 11487-AcQHnP_UYiXFks8AED1NLzHgG88AAAGOvS1YoQ
.analytics.yahoo.com/ Name: IDSYNC
Value: "19cy~2hqy:18xp~2hqy:18z8~2hqy"
.ad-m.asia/ Name: uid
Value: 1YZ31aZi7vV
.pubmatic.com/ Name: KRTBCOOKIE_904
Value: 23554-FtFHoc1mAHGElrLW4cETZg&KRTB&23557-FtFHoc1mAHGElrLW4cETZg
.uncn.jp/ Name: t
Value: v_0aee8959-95b5-44d8-b5fe-8c752d28d8f0
.pubmatic.com/ Name: KRTBCOOKIE_1201
Value: 23170-v_0aee8959-95b5-44d8-b5fe-8c752d28d8f0&KRTB&23180-v_0aee8959-95b5-44d8-b5fe-8c752d28d8f0&KRTB&23547-v_0aee8959-95b5-44d8-b5fe-8c752d28d8f0
.rfihub.com/ Name: eud
Value: H4sIAAAAAAAA_9vEyGtobmhkam5gYWJpYm65ShzBt7A0MwEAEzR_VyAAAAA
.pubmatic.com/ Name: KRTBCOOKIE_18
Value: 22947-1972084074811822544
.rubiconproject.com/ Name: receive-cookie-deprecation
Value: 1
.admatrix.jp/ Name: uid
Value: ffc44cd9-da0b-414f-ab87-0d51a187b3c6
.adform.net/ Name: C
Value: 1
.semasio.net/ Name: SEUNCY
Value: B5A32201CA10E7EC
.adform.net/ Name: uid
Value: 8886163999501012041
.infolinks.com/ Name: KADUSERCOOKIE
Value: FF0D79E1-DC81-450A-B58D-92B7449448CF~1712578625575
.linkedin.com/ Name: bcookie
Value: "v=2&8fbc7324-4d6d-4623-8994-0ee1ee091d70"
.linkedin.com/ Name: lidc
Value: "b=OGST05:s=O:r=O:a=O:p=O:g=3022:u=1:x=1:i=1712570849:t=1712657249:v=2:sig=AQGMaC3VtUTqkGowwnxrfIYZzmD7Moj2"
.pubmatic.com/ Name: KRTBCOOKIE_391
Value: 22924-8886163999501012041&KRTB&23263-8886163999501012041&KRTB&23481-8886163999501012041
.pubmatic.com/ Name: KRTBCOOKIE_943
Value: 19522-AtxLB81ytUV&KRTB&23501-AtxLB81ytUV
.dotomi.com/ Name: DotomiTest
Value: 1840250d9bde1fae
.oncozine.com/ Name: _ym_isad
Value: 2
.yandex.ru/ Name: yuidss
Value: 4865671391712570848
.yandex.ru/ Name: ymex
Value: 2027930849.yrts.1712570849#2027930848.yrtsi.1712570848
.yandex.ru/ Name: bh
Value: Ej4iR29vZ2xlIENocm9tZSI7dj0iMTIzIiwiTm90OkEtQnJhbmQiO3Y9IjgiLCJDaHJvbWl1bSI7dj0iMTIzIhoFIng4NiIiECIxMjMuMC42MzEyLjEwNSIqAj8wOgciV2luMzIiQggiMTAuMC4wIkoEIjY0IlJbIkdvb2dsZSBDaHJvbWUiO3Y9IjEyMy4wLjYzMTIuMTA1IiwiTm90OkEtQnJhbmQiO3Y9IjguMC4wLjAiLCJDaHJvbWl1bSI7dj0iMTIzLjAuNjMxMi4xMDUiIg==
.crwdcntrl.net/ Name: _cc_dc
Value: 2
.crwdcntrl.net/ Name: _cc_id
Value: f5aca4d12dbd6df45bb97d89e0ca6d08
.oncozine.com/ Name: _ym_visorc
Value: w
.primis.tech/ Name: csuuid
Value: 6613c1e19ba43
.w55c.net/ Name: wfivefivec
Value: y03Xvv5k1RTLUt5
.pubmatic.com/ Name: KRTBCOOKIE_32
Value: 11175-AAALSAcU1zsq1AMOtV2wAAAAAAA&KRTB&22713-AAALSAcU1zsq1AMOtV2wAAAAAAA&KRTB&22715-AAALSAcU1zsq1AMOtV2wAAAAAAA&KRTB&23519-AAALSAcU1zsq1AMOtV2wAAAAAAA
pool.admedo.com/ Name: tuuid
Value: 42bc5540-fc92-4726-9e0c-6b938003dcd7
pool.admedo.com/ Name: c
Value: 1712570849
pool.admedo.com/ Name: tuuid_lu
Value: 1712570849
.w55c.net/ Name: matchpubmatic
Value: 5
.pubmatic.com/ Name: KRTBCOOKIE_107
Value: 1471-uid:y03Xvv5k1RTLUt5&KRTB&23421-uid:y03Xvv5k1RTLUt5
.pubmatic.com/ Name: KRTBCOOKIE_466
Value: 16530-53825eb4-6ef5-4eed-b252-2e758860640f
.connatix.com/ Name: cnx_userId
Value: 4d6ea499d55245a2853d888c396006c7
.intentiq.com/ Name: intentIQ
Value: PQ6TjtZX1Y
.intentiq.com/ Name: IQver
Value: 1.9
.mathtag.com/ Name: uuid
Value: 188e6613-c1e1-4800-aa95-bada0b7a82d7
.pubmatic.com/ Name: KRTBCOOKIE_27
Value: 16735-uid:188e6613-c1e1-4800-aa95-bada0b7a82d7
.lijit.com/ Name: _ljtrtb_80
Value: LUQSGSA9-1C-33P2
.creativecdn.com/ Name: g
Value: LQZVC7LNBut8qiu0imQr_1712570849936
.creativecdn.com/ Name: ts
Value: 1712570849
.intentiq.com/ Name: CSDT
Value: UEQ6MTUxMDZfMCZVOUxZbDFj
.intentiq.com/ Name: ASDT
Value: 0
.intentiq.com/ Name: intentIQCDate
Value: 1712570849983
.intentiq.com/ Name: IQPData
Value: 533500327#1712570849981#0#1712570849981
sync.srv.stackadapt.com/ Name: sa-user-id
Value: s%3A0-e63d1ffa-2d66-5cbb-7de0-fedff7c75e06.aeMB9WVNZJaugg0Xey73bll85uOvOongfZa7Q3wQRo0
.srv.stackadapt.com/ Name: sa-user-id
Value: s%3A0-e63d1ffa-2d66-5cbb-7de0-fedff7c75e06.aeMB9WVNZJaugg0Xey73bll85uOvOongfZa7Q3wQRo0
sync.srv.stackadapt.com/ Name: sa-user-id-v2
Value: s%3A5j0f-i1mXLt94P7f98deBh_Mkac.sx0%2FCIOOjnPfB6RdkLygXbHyvXiTm3fyhMrMsXxK7D8
.srv.stackadapt.com/ Name: sa-user-id-v2
Value: s%3A5j0f-i1mXLt94P7f98deBh_Mkac.sx0%2FCIOOjnPfB6RdkLygXbHyvXiTm3fyhMrMsXxK7D8
sync.srv.stackadapt.com/ Name: sa-user-id-v3
Value: s%3AAQAKIL8C1RMZStzVfkGKTl87vkx3AP868Yef8RmwzzMedP36EGcYBCDig8-wBjABOgSw8hAxQgR75UhQ.n4o%2FZiRu2U4gk8mMluqzC75AUJIsHOCYpRhIT%2BBxbtU
.srv.stackadapt.com/ Name: sa-user-id-v3
Value: s%3AAQAKIL8C1RMZStzVfkGKTl87vkx3AP868Yef8RmwzzMedP36EGcYBCDig8-wBjABOgSw8hAxQgR75UhQ.n4o%2FZiRu2U4gk8mMluqzC75AUJIsHOCYpRhIT%2BBxbtU
.pubmatic.com/ Name: KRTBCOOKIE_860
Value: 16335-5j0f-i1mXLt94P7f98deBh_Mkac&KRTB&23334-5j0f-i1mXLt94P7f98deBh_Mkac&KRTB&23417-5j0f-i1mXLt94P7f98deBh_Mkac&KRTB&23426-5j0f-i1mXLt94P7f98deBh_Mkac
.adx.opera.com/ Name: UID
Value: OPU61b36f24cbaa425d9335e8e5298c1f64
.pubmatic.com/ Name: KRTBCOOKIE_1323
Value: 23480-OPU61b36f24cbaa425d9335e8e5298c1f64&KRTB&23485-OPU61b36f24cbaa425d9335e8e5298c1f64&KRTB&23575-OPU61b36f24cbaa425d9335e8e5298c1f64
.csync.loopme.me/ Name: viewer_token
Value: 731f726b-52f3-4a02-94cc-696d15c7fa22
.pubmatic.com/ Name: KRTBCOOKIE_632
Value: 23041-AmdbEmFL-NMXfs-2nZdLK_Us7nCwc4yXM7ANfKRA5CM&KRTB&23047-AmdbEmFL-NMXfs-2nZdLK_Us7nCwc4yXM7ANfKRA5CM&KRTB&23234-AmdbEmFL-NMXfs-2nZdLK_Us7nCwc4yXM7ANfKRA5CM&KRTB&23361-AmdbEmFL-NMXfs-2nZdLK_Us7nCwc4yXM7ANfKRA5CM
.pubmatic.com/ Name: PugT
Value: 1712539901
.ipredictive.com/ Name: cu
Value: 33f96023-76a4-455e-91e9-4156a7feab31|1712570850269
www.oncozine.com/ Name: izootoWpConfig
Value: %7B%22b_type%22:1,%22d_type%22:1,%22evt_trk%22:1,%22izooto_uid%22:%2252bc2733-bdd4-4621-9d5d-52588ea835b7%22%7D
.rubiconproject.com/ Name: audit
Value: 1|nHPRQHW3tM+SMmIcRN+BqCDp+6IYomkJpeCQxs8W6zoNIXVBPorKWs1KEDYHAcrU7DDGzGcRo3MiZ07GJqnMnujPGTiJ9gcmpmvllXEtYN4=
.pubmatic.com/ Name: SPugT
Value: 1712570859
.ads.pubmatic.com/ Name: KCCH
Value: YES
.pubmatic.com/ Name: chkChromeAb67Sec
Value: 7
.pubmatic.com/ Name: pi
Value: 156423:4
.ads.pubmatic.com/ Name: pubsyncexp
Value: 1712592452449

1001 Console Messages

Source Level URL
Text
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.
other warning URL: https://www.oncozine.com/u-s-fda-approves-phase-3-study-design-for-zilovertamab-in-the-treatment-of-mantle-cell-lymphoma/
Message:
Third-party cookie will be blocked. Learn more in the Issues tab.

Indicators

This is a term in the security industry to describe indicators such as IPs, Domains, Hashes, etc. This does not imply that any of these indicate malicious activity.

academia.trendmd.com
cc.trendmd.co
cdn.ampproject.org
cdn.izooto.com
cdn.ywxi.net
cloud.tnewstraffic.com
csi.gstatic.com
css.trendmd.com
fonts.googleapis.com
fonts.gstatic.com
googleads.g.doubleclick.net
imasdk.googleapis.com
js.trendmd.com
mc.yandex.ru
pagead2.googlesyndication.com
resources.infolinks.com
router.infolinks.com
rt3073.infolinks.com
s3-us-west-2.amazonaws.com
secure.gdcstatic.com
securepubads.g.doubleclick.net
trendmd.s3.amazonaws.com
www.facebook.com
www.google-analytics.com
www.googletagmanager.com
www.oncozine.com
www.trendmd.com
www.trustedsite.com
cloud.tnewstraffic.com
mc.yandex.ru
142.250.196.142
142.251.42.194
172.217.175.72
172.66.41.9
172.66.42.247
172.67.159.150
172.67.204.94
216.58.220.130
2404:6800:4004:80b::200e
2404:6800:4004:80f::2003
2404:6800:4004:81e::2008
2404:6800:4004:81e::200a
2404:6800:4004:821::2002
2404:6800:4004:821::200a
2404:6800:4004:825::2001
2600:9000:2157:e400:14:6bfc:5740:93a1
2606:4700:3035::6815:1167
2606:4700::6812:d841
2606:4700::6812:d941
2a00:1450:4010:c06::78
2a02:6b8::1:119
2a03:2880:f10f:83:face:b00c:0:25de
34.149.36.179
52.38.207.187
52.92.148.72
54.231.132.161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